Download Published Abstracts

C. H. van Dyck, M.D.
May 3, 2017
CURRICULUM VITAE
Christopher H. van Dyck, M.D.
Home Address:
Home Phone:
KS
376 Sperry Road, Bethany, CT 06524
(203) 393-2215
Office Address:
Alzheimer’s Disease Research Unit
Yale University School of Medicine
One Church Street, Suite 600
New Haven, CT 06510
Email Address:
Website:
Office Phone:
Office Fax:
[email protected]
http://www.alzheimers.yale.edu
(203) 764-8100
(203) 764-8111
Birth Date: 8/25/55
Birth Place: Wichita,
Education:
BA
MD
Yale College, 1978 (cum laude)
Northwestern University Medical School, 1984
Career:
1984-1985
1985-1988
1988-1990
1990-1991
1991-1992
1992-1997
1988-Present
1990-Present
1992-Present
1997-2007
2002-2007
Internship in Internal Medicine, Norwalk Hospital, Norwalk, CT
Residency in Psychiatry, Yale University School of Medicine, New
Haven, CT
Fellowship in Geriatric Psychiatry, Yale University School of
Medicine, New Haven, CT
Research Fellowship, Department of Psychiatry, Yale University
School of Medicine, New Haven, CT
Associate Research Scientist, Department of Psychiatry, Yale
University School of Medicine, New Haven, CT
Assistant Professor of Psychiatry, Yale University School of Medicine,
New Haven, CT
Consultant in Geriatric Psychiatry, Adler Geriatric Assessment Center,
Yale New Haven Hospital, New Haven, CT
Attending, Yale New Haven Hospital, New Haven, CT
Director, Alzheimer's Disease Research Unit, Department of
Psychiatry, Yale University School of Medicine, New Haven, CT
Associate Professor of Psychiatry, Yale University School of
Medicine, New Haven, CT
Associate Professor of Neurobiology (Secondary Appointment), Yale
University School of Medicine, New Haven, CT
1
C. H. van Dyck, M.D.
2006-Present
2007-Present
May 3, 2017
Director, Division of Aging and Geriatric Psychiatry, Department of
Psychiatry, Yale University School of Medicine
Professor of Psychiatry and Neurobiology, Yale University School of
Medicine, New Haven, CT
Licensure:
Connecticut License #027403
National Provider Identifier (NPI) 1821088188
Board Certification:
American Board of Psychiatry and Neurology:
Psychiatry (October 1991) Certificate #34888
Added Qualifications in Geriatric Psychiatry (April 1994, 2005) Certificate #1242
Professional Honors or Recognition:
1973
1978
1983
1984
1995
1996
1997-Present
2000
2001
2004
2004
2005-Present
2005
2006
2009
National Merit Scholarship
Departmental Distinction in the Major (Philosophy), Yale University
Rock Sleyster Memorial Scholarship in Psychiatry
Paolo Raimondi Memorial Award for Humanism in Medicine,
Northwestern University
American Federation for Aging Research (AFAR) Grant Award
Junior Investigator Award, American Association for Geriatric
Psychiatry
Top Doctors: New York Metro Area, Selected by Castle Connolly
Medical, Ltd.
NARSAD Independent Investigator Award
Alzheimer’s Association Investigator-Initiated Research Grant Award
American Health Assistance Foundation Research Grant Award
Ethel F. Donaghue Women’s Health Investigator Award
Best Doctors in New York (Top 2%), as Featured in New York
Magazine
“Compassion and Cure” Award, Alzheimer’s Association
Top 10 articles in Neuropsychopharmacology of 2006 (at ACNP
meeting; Zdanys et al, 2007)
Honorary Master of Arts Privatim degree, Yale University
Departmental, Medical School, and University Committees:
1995-Present
1996-1998
1997-Present
1997-Present
Departmental Task Force for Geriatric Psychiatry
Quality Assurance, Yale New Haven Hospital (Psychiatry Department
Representative
Executive Committee, Neurochemical Brain Imaging Program, Yale
University School of Medicine.
Fellow, Calhoun College, Yale University.
2
C. H. van Dyck, M.D.
1998-2000
2002-2003
2003-2005
2007
May 3, 2017
Credentials Committee, Yale New Haven Hospital
Departmental Task Force for Research Protocol Review
Yale-Pfizer Joint Science Committee
Yale Human Investigation Committee, Policy Meeting “Considerations
for involving permanently or transiently decisionally impaired subjects
in research.”
Other Professional Activities:
Memberships:
Society for Neuroscience
Society of Nuclear Medicine
International Society for Neuroimaging in Psychiatry
American Association for Geriatric Psychiatry; Research Committee; Member in
Training Award Committee; Early Career Scientist Award Committee; Distinguished
Scientist Award Committee (Chairman 2009-2010).
American Psychiatric Association
Connecticut Psychiatric Society; member, Geriatric Psychiatry Committee
Editorial Boards, Journal Referees, Grant Reviews:
2000-Present
2004-Present
2007-Present
2007-Present
2007-Present
2010-
Editorial Board, Journal of Nuclear Medicine.
Editorial Board, Current Medical Imaging Reviews (Bentham
Sciences).
Editorial Board, Brain Imaging and Behavior (Springer).
Editorial Board, The Open Medical Imaging Journal (Bentham
Sciences). [6/1/10: still active*]
Editorial Board, The Open Neuroimaging Journal (Bentham Sciences).
[6/1/10: still active*]
Editorial Board (Associate Editor), Journal of Alzheimer's Disease
Journal Referee for Journal of Nuclear Medicine, Journal of Cerebral Blood Flow and
Metabolism, Psychiatry Research: Neuroimaging, Journal of
Neuroscience, Neuroscience Letters, Biological Psychiatry, Journal of
Neuropsychiatry and Clinical Neurosciences, Life Sciences, Magnetic
Resonance Imaging, American Journal of Geriatric Psychiatry, and
Current Medical Imaging Reviews.
Abstract Reviewer for: American Association for Geriatric Psychiatry Annual Meeting,
Brain’05 and BrainPET’05, June 7-11, 2005, Vrije Universiteit,
Amsterdam.
2002-Present
Research Grant Reviewer for Alzheimer’s Association
3
C. H. van Dyck, M.D.
2003-Present
May 3, 2017
Grant Reviewer for National Institute of Health, Center for Scientific
Review, Brain Disorders and Clinical Neurosciences ZRG1 BDCN-2
(02), William C Benzing, Ph.D., SRA.
INDs Sponsored:
2001-2010:
2001-Present:
IND #61,156, “Evaluation of [I-123]5-I-A-85380 as a SPECT Tracer
to Image Nicotinic Acetylcholine Receptors in Brain.”
“IND #42,798, “Evaluation of [123I](1R)-ß-CIT as a SPECT Marker
of Striatal Monoaminergic Innervation.”
Consulting / Scientific Advisory Boards
1988-Present
1990-2003
2000-2003
1995-Present
1996-1998
2000-2001
1997-2001
2001-2002
2/23-25/03
2003-2008
2003-2005
Consultant in Geriatric Psychiatry, Adler Geriatric Assessment Center,
Yale New Haven Hospital, New Haven, CT
Consultant in Geriatric Psychiatry, Bentley Gardens Health Care Ctr,
West Haven, CT
Consultant in Geriatric Psychiatry, Soundview Convalescent Home,
West Haven, CT
Legal Consultant (to various attorneys) regarding decision making
capacity in Alzheimer’s disease and related disorders, and regarding
risk factors for developing Alzheimer’s disease and related disorders
Scientific Advisory Board, Mediolanum Pharmaceuticals (regarding
SPECT imaging studies in Alzheimer’s disease)
Consultant to Pfizer, Inc for staff training in Alzheimer’s disease
Designed, organized, and presented training preceptorships (primarily
for marketing staff) in the basic neurobiology, clinical
presentation/evaluation, and pharmacological treatment of
Alzheimer’s disease.
Consultant to SCIREX Corporation (CRO) regarding Alzheimer’s
disease clinical trials
Evaluated sponsor FDA protocols. Assisted in preparation and
presentation of proposals for CRO conduct of protocols. Served as
consultant and medical monitor during conduct of Alzheimer’s disease
clinical trials. Provided staff training and education in Alzheimer’s
disease for staff of CRO and sponsoring pharmaceutical companies.
Presented at Investigator Meetings.
Consultant to Biovail Corporation regarding Alzheimer’s disease
clinical trials
Evaluated preclinical literature and sponsor FDA protocols. Attended
meetings with sponsor.
Invited Participant, Janssen CNS Advisory Summit, Scottsdale AZ.
Scientific Advisory Board, Forest Laboratories.
Consultant, Pilot Collaborative PET Imaging Trial (5 R01
AG022394-02, P.I. Norman Foster, University of Michigan Health
System).
4
C. H. van Dyck, M.D.
2005-Present
2008-Present
2009-Present
2010-Present
2010-Present
May 3, 2017
Expert for the NIH Genetic Association Database
(http://geneticassociationdb.nih.gov) for: ApoE4 and Alzheimer’s
Disease; Dopamine Transporter (SLC6A3); Serotonin Transporter
(SLC6A4)
Scientific Advisory Board, Bristol-Myers Squibb (regarding
Alzheimer’s disease and clinical trial design)
Scientific Advisory Board, GlaxoSmithKline (regarding Alzheimer’s
disease and FDA clinical study report)
Scientific Advisory Board, Pfizer, Inc and Janssen Immunotherapy
(regarding Alzheimer’s disease anti-amyloid therapeutics and
vasogenic edema)
Scientific Advisory Board, Elan Pharmaceuticals (regarding
Alzheimer’s disease and investigational therapeutic agent)
Speakers Bureaus:
2000-2003
2000-2002
2002-2004
2003-2005
Pfizer Pharmaceuticals
Novartis Pharmaceuticals
Janssen Pharmaceuticals
Forest Laboratories
Lectures, Courses:
10/27/93
11/14/93
1/28/94
1994-1996
6/7/94
12/14/94
1995-1997
4/4/95
6/26/96
7/17/96
Invited Speaker, Alzheimer's Association, South Central Connecticut
Chapter
Invited Speaker, Alzheimer's Association, South Central Connecticut
Chapter: “New Treatments for Alzheimer's Disease.” Stratford, CT.
Presenter, Research Forum, Department of Psychiatry, Yale University
School of Medicine
Guest Lecturer, Shoals Marine Laboratory (Cornell University),
Appledore, Maine (Neurobiology of Animal Behavior)
Invited Speaker, Society of Nuclear Medicine, Technologists
Section:“SPECT Imaging of Alzheimer's Disease.” Orlando, FL.
Invited Speaker, Yale Program on Aging and Claude D. Pepper Older
Americans Independence Center: “Imaging the Aging Dopamine
System with SPECT.”
Lecturer, Geriatric Resource Nurse Program Conference, Yale
University School of Nursing
Invited Speaker, Geriatric Seminar Series, Department of Psychiatry,
The New York-Cornell Medical Center, Westchester Division:
“SPECT Imaging in Normal Aging and Alzheimer's Disease.”
Invited Speaker, Alzheimer's Association, Southern Connecticut
Chapter: “Genetics of Alzheimer's Disease.”
Invited Speaker, Southern Connecticut State University: “New
Developments in Alzheimer's Disease.”
5
C. H. van Dyck, M.D.
3/3/97
3/18/98
4/20/98
10/16/98
5/7/99
2/19/00
3/2/00
3/13/00
3/15/00
4/13/00
4/24/00
4/28/00
9/5/00
9/14/00
10/12/00
May 3, 2017
Symposium Speaker and Chairman, American Association for
Geriatric Psychiatry: “Imaging the Aging Dopamine System.”
(educational symposium for annual meeting of AAGP)
Invited Speaker, Connecticut Psychiatric Society Resident’s Day,
Berlin CT: “Topics in Alzheimer's Disease: Clinical Genetics and
Current Treatments.”
Invited Speaker, 1998 Neuroscience Symposium on “Aging,”
sponsored by The Western North Carolina Chapter of the Society for
Neuroscience and The Center for Investigative Neuroscience: “AgeRelated Decline in Dopamine Transporters with [123I]ß-CIT SPECT.”
Invited Speaker, Continuing Medical Education conference on “New
Diagnostic & Management Strategies for Dementia” sponsored by
Yale University School of Medicine Section of Geriatrics:
“Developments in Pharmacologic Treatment of Cognitive Impairment
and Dementia.”
Invited Speaker, Alzheimer's Association, Southern Connecticut
Chapter: “Memory and Aging.”
Invited Speaker, Section of Neurobiology, Yale University School of
Medicine, Woods Hole Retreat Symposium: “Neuroimaging
Correlates of Apolipoprotein E-4 in Alzheimer's Disease” Woods
Hole, MA.
Invited Speaker, Alzheimer's Association, Southern Connecticut
Chapter: “Pharmacologic Treatment of Alzheimer’s Disease.” Chester
CT.
Symposium Speaker and Chairman, American Association for
Geriatric Psychiatry: “Neuroimaging Correlates of ApoE 4 in
Alzheimer's Disease and Healthy Aging.” (educational symposium for
annual meeting of AAGP)
Invited Discussant, Luncheon Roundtable on “Neuroimaging.”
(educational roundtable for annual meeting of AAGP)
Invited Speaker, National Center of Excellence in Women’s Health at
Yale and the Women’s Behavioral Health Division: “Estrogen
Replacement Therapy for Treatment of Mild to Moderate Alzheimer’s
Disease: A One-Year Randomized controlled Trial.”
Invited Speaker, Preceptorship in Psychiatry, sponsored by Pfizer Inc:
“Alzheimer’s Disease” at Yale University School of Medicine.
Invited Speaker, Alzheimer’s Association (Connecticut) Education
Conference: “Pharmacological Treatment of Alzheimer’s Disease:
Present and Future.”
Invited Speaker, Preceptorship in Psychiatry, sponsored by Pfizer Inc:
“Alzheimer’s Disease” at Yale University School of Medicine.
Invited Speaker, educational dinner on “Alzheimer’s Disease”
sponsored by Novartis Pharmaceuticals. New Haven, CT.
Invited Speaker, Symposium on “Cognition Enhancers, AntiAlzheimer and Neuroprotective Drugs” sponsored by the Institute for
the Study of Aging and the Department of Pharmacology, Yale
6
C. H. van Dyck, M.D.
10/20/00
1/16/01
3/8/01
5/16/01
11/15/01
1/14/02
2/20/02
4/20/02
12/9/02
1/28/03
2/12/03
5/8/03
5/10/03
9/6/03
11/1/03
11/6/03
May 3, 2017
University School of Medicine: “Neuroimaging in Alzheimer’s
Disease: Relevance for the Development of Therapeutic Agents.”
Invited Speaker, Yale Psychiatric Alumni Association Meeting,
featuring Contemporary Treatments in Geriatric Psychiatry: “Current
and Future Pharmacologic Treatments for Alzheimer’s Disease.”
Course Director and Speaker, Preceptorship in Alzheimer’s Disease,
sponsored by Pfizer Inc. at Yale University School of Medicine.
Course Director and Speaker, Preceptorship in Alzheimer’s Disease,
sponsored by Pfizer Inc. at Yale University School of Medicine.
Invited Speaker, Connecticut Geriatric Society, Stamford CT: “AgeRelated Memory Loss: Is It Ever Benign?”
Invited Speaker, educational dinner on “Mild Cognitive Impairment”
sponsored by Pfizer Pharmaceuticals. Westport, CT.
Invited Speaker (Grand Rounds), Milford Hospital, Milford CT: “Early
Diagnosis & Treatment for Alzheimer’s.”
Invited Speaker (Grand Rounds), Masonic Home, Wallingford CT:
“Mild Cognitive Impairment.”
Invited Speaker, Neuroscience 2002 Symposium, “New Mechanisms:
New Treatments” sponsored by Department of Psychiatry Yale
University School of Medicine in Association with National Alliance
for the Mentally Ill: “Alzheimer’s Disease: Pharmacotherapy and Brain
Function.”
Study Group Speaker, 41st Annual Meeting of the American College of
Neuropsychopharmacology, San Juan PR: “Dopamine transporters in
ADHD: Increased, decreased, or unchanged?”
Invited Speaker (Grand Rounds), University of Connecticut,
Farmington CT: “The Diagnosis and Treatment of Alzheimer’s
Disease.”
Invited Speaker (Medical Grand Rounds), Baystate Medical Center,
Springfield MA: “Pharmacologic Treatment of Alzheimer’s Disease
and Mild Cognitive Impairment.”
Invited Speaker (Grand Rounds), Institute of Living, Hartford CT:
“Pharmacologic Treatment of Alzheimer’s Disease and Mild Cognitive
Impairment.”
Invited Speaker, 6th International Conference AD/PD, Seville, Spain.
“Memantine/Donepezil Dual Therapy is Superior to
Placebo/Donepezil Therapy for Moderate to Severe Alzheimer’s
Disease.”
Invited Speaker, CME, Inc, Iselin NJ: “Alzheimer’s Disease:
Diagnosis and Medication Mechanism of Actions to Maximize Patient
Outcomes.”
Invited Speaker, CME, Inc, Raleigh NC: “Alzheimer’s Disease:
Diagnosis and Medication Mechanism of Actions to Maximize Patient
Outcomes.”
Invited Speaker, CME Symposium on “Emerging Management
Strategies in Alzheimer’s Disease” sponsored by University of
Minnesota, held in Boston, MA: “Maximizing Therapeutic Response:
7
C. H. van Dyck, M.D.
11/8/03
12/1/03-4/28/04
2/3/04
2/24/04
4/15/04
4/28/04
7/13/04
10/30/04
3/31/05
5/13/05
6/18/05
12/13/05
2/15/06
6/21/06
11/28/06
May 3, 2017
A Combination Approach to the Management of Alzheimer’s
Disease.”
Invited Speaker, CME, Inc, Newark NJ: “Alzheimer’s Disease:
Diagnosis and Medication Mechanism of Actions to Maximize Patient
Outcomes.”
Faculty Speaker, "A Unique Advance in Alzheimer's Disease: The
Namenda Teleconference Series," sponsored by Forest Laboratories.
Invited Speaker, Adler Geriatric Assessment Center: “Memantine for
Moderate to Severe Alzheimer’s Disease.”
Invited Speaker, Symposium on “Assessing Current Practice In
Alzheimer’s Disease” at AAGP annual meeting, Baltimore MD: “The
ABCs of Alzheimer’s Disease Management: Understanding the Latest
Advances in Pharmacologic and Nonpharmacologic Interventions for
Alzheimer’s Disease.”
Invited Speaker, educational dinner on “Alzheimer’s Disease”
sponsored by Forest Pharmaceuticals. Ledyard, CT.
Invited Speaker (Grand Rounds), Northampton VA Medical Center,
Leeds MA: “Alzheimer's Disease Update: Current Status of
Pathophysiology, Diagnosis, and Treatment.”
Invited Speaker, Alzheimer’s Association Connecticut Chapter Future
Forum, West Haven, CT.
Invited Speaker, Massachusetts Psychiatric Society 2nd Annual
Geriatric Psychiatry Conference: Controversies in Geriatric Psychiatry,
Waltham MA: “Cholinesterase Inhibitors and Memantine: Just How
Worthwhile are these Agents?”
Invited Speaker, 2005 CT Alzheimer’s Association Educational
Conference, Cromwell, CT: “Pharmacologic Treatments for
Alzheimer's Disease: How Worthwhile are They?”
Invited Speaker, Grand Rounds, Department of Psychiatry, Yale
University School of Medicine: “Alzheimer’s Disease Update: The
Treatment and The Story.” “How Worthwhile are Approved
Treatments?”
Invited Speaker, Categorical Seminar on “Dementia Imaging:
Metabolism, Blood Flow, and Beyond,” Society of Nuclear Medicine
Annual Meeting, Toronto, CA: “Clinical Features of Dementia:
Evaluation, Disease Course, and Treatment.”
Invited Speaker, Adler Geriatric Assessment Center, Yale-New Haven
Hospital: “PET Imaging for the Clinical Evaluation of Dementia.”
Invited Speaker (Grand Rounds), Institute of Living, Hartford CT:
“Pharmacologic Treatments for Alzheimer’s Disease: How
Worthwhile Are They?”
Invited Speaker, Neurology/Neurosurgery Clinical Neuroscience
Grand Rounds, Yale University School of Medicine: “The
Apolipoprotein E4 Phenotype in Alzheimer's Disease.”
Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale
University School of Medicine: “Present and Future Drug Therapy of
Alzheimer’s Disease.”
8
C. H. van Dyck, M.D.
11/29/07
12/16/08
5/26/09
11/9/09
3/1/10
3/2/10
3/23/10
6/17/10
May 3, 2017
Invited Speaker, CT Alzheimer’s Association, Kensington, CT:
Progress of Research and Treatment of Alzhemer’s Disease, “Is There
Light at the End of the Tunnel?”
Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale
University School of Medicine: “New and Emerging Treatments for
Alzheimer’s Disease.”
Invited Speaker, Grand Rounds, St. Vincent’s Medical Center,
Bridgeport, CT: “Approved & Investigational Treatments for
Alzheimer's Disease.”
Invited Speaker, CT Alzheimer’s Association, Hamden, CT:
“Overview of Alzheimer’s Disease & Other Forms of Dementia and
Treatment/Research.”
Invited Speaker, Yale Club of New York, New York, NY. Alzheimer’s
Disease: The Science, The Story and Yale Reception and Presentation:
“ß-Amyloid Imaging in Subjects at Risk for Alzheimer’s Disease.”
Invited Speaker, Grand Rounds, Section of Geriatric Medicine, Yale
University School of Medicine: “New and Emerging Treatments for
Alzheimer’s Disease.”
Invited Speaker, CT Alzheimer’s Association, Statewide Education
Conference, Cromwell, CT: “Toward Primary Prevention Trials: AntiAmyloid Therapies and Amyloid Imaging in Individuals at Risk
for Alzheimer’s Disease.”
Invited Speaker, CT Alzheimer’s Association, New Canaan, CT: “New
Medical Research for Individuals at Risk for Alzheimer’s Disease.”
Other:
1993-Present
1993-Present
1994-Present
1994-Present
1997-2002
1997-2002
2000-2002
2001-Present
2002-Present
2004-Present
Faculty, Program on Aging, Yale University School of Medicine
Faculty, Claude D. Pepper Older Americans Independence Center,
Yale University School of Medicine
Adjunct Faculty, Fellowship in Geriatric Medicine and Clinical
Epidemiology, Department of Medicine, Yale University School of
Medicine
Faculty, Fellowship in Geriatric Psychiatry, Department of Psychiatry,
Yale University School of Medicine
Board of Directors, Alzheimer's Association, Southern Connecticut
Chapter
Program Committee, Alzheimer's Association, Southern Connecticut
Chapter
Member of “Ask the Experts” panel (expert on Alzheimer’s disease)
for HealthInfo web-based educational corporation.
Steering Committee, Alzheimer’s Disease Cooperative Study (ADCS;
NIH/NIA Consortium)
Chairman, Medical Scientific Advisory Committee, Alzheimer's
Association, Connecticut Chapter
Steering Committee, Alzheimer’s Disease Neuroimaging Initiative
(ADNI; NIH/NIA Consortium)
9
C. H. van Dyck, M.D.
2006-Present
2007-Present
May 3, 2017
Genetics Working Group, Alzheimer’s Disease Neuroimaging
Initiative (ADNI; NIH/NIA Consortium)
Member, Interdepartmental Neuroscience Program (INP), Yale
University
10
C. H. van Dyck, M.D.
May 3, 2017
Grant and Contracts Received:
Active
Agency: NIH/NIA
Grant Number: 1-R01-AG030457-01A1
Title of Grant: Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly
Subjects
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $1,377,071 / $832,067
Dates of Project: 9-15-08 to 8-31-11; NCE to 8-31-12
Agency: NIH/NIA
Grant Number: 1-R01-AG034953-01 (P.I. Doug Rothman)
Title of Grant: 13C MRS Studies of Human Brain Mitochondrial Metabolism in Healthy
Aging Subjects
Role on Project: Co-Investigator
Total Costs / Total Direct Costs: $2,052,625 / $1,240,257
Dates of Project: 7-1-10 to 6-30-14
Agency: NIH/NIA
Grant Number: 2-U01AG024904-06 (P.I.: Michael W. Weiner)
Title of Grant: Alzheimer's Disease Neuroimaging Initiative (ADNI)
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $400,000 / $320,000 (est.)
Dates of Project: 9/30/2010 to 8/31/2015
Agency: NIH/NIA
Grant Number: 5-U01-AG10483 (P.I. Paul Aisen)
Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $500,000 / $400,000 (est.)
Dates of Project: 7-1-06 to 6-30-12
Specific Projects thus far: 1) “Assessment Measures for Alzheimer’s Disease Primary
Prevention Trials,” 2) “A Multicenter, Randomized, Double-Blind, PlaceboControlled Trial of Simvastatin to Slow the Progression of Alzheimer’s Disease,” 3)
“Study of High Dose Supplements to Reduce Homocysteine and Slow the Rate of
Cognitive Decline in Alzheimer’s Disease” (HIC #23455), 4) “A Randomized,
Double-Blind, Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid
(DHA) in Slowing the Progression of Alzheimer’s Disease” (HIC #0610001926), 5)
“Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer
Disease Prevention Research in People Over 75 Years Old” (HIC #0709003080), 6)
“A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating
The Efficacy And Safety Of Eighteen Months Of Treatment With PF-04494700
(TTP488) In Participants With Mild-To-Moderate Alzheimer’s Disease” (HIC
11
C. H. van Dyck, M.D.
May 3, 2017
#801003458), 7) “A Randomized, Double-Blind, Placebo-Controlled, Two DoseArm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous
(Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer’s
Disease” (HIC#: 0811004451).
Agency: NIH/NIA
Grant Number: 1 RC2 AG036535 (P.I.: Michael W. Weiner)
Title of Grant: Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
(ADNI-GO)
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $125,000 / $100,000 (est.)
Dates of Project: 10/01/09 to 8/31/11
Agency: Genentech, Inc
Title of Grant: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in
Patients with Mild to Moderate Alzheimer’s Disease (protocol number ABE4869g).” HIC
#1103008271
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $
Dates of Project: 11-15-11 to 7-1-15
Agency: Wyeth Research
Title of Grant: “A Phase 2, Multicenter, 24-Month, Randomized, Third-Party Unblinded,
Placebo-Controlled, Parallel-Group Amyloid Imaging Positron Emission Tomography
(PET) and Safety Trial of ACC-001 and QS-21 Adjuvant in Subjects with Early
Alzheimer’s Disease.” HIC #1101007937
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $
Dates of Project: 6-13-11 to 7-1-14
Agency: Wyeth Research
Title of Grant: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Efficacy and Safety Trial of Bapinezumab (AAB-001, ELN115727) in
Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Noncarriers (protocol number 3133K1-3000-US).” HIC: #1010007501
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 3-1-11 to 12-1-13
Agency: Wyeth Research
Title of Grant: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Efficacy and Safety Trial of Bapinezumab (AAB-001, ELN115727) in
Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4
Carriers (protocol number 3133K1-3001-US).” HIC: #911005961
Role on Project: Principal Investigator
12
C. H. van Dyck, M.D.
May 3, 2017
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 5-1-10 to 5-1-13
Agency: Eli Lilly and Company
Title of Grant: “Effect of LY2062430, an Anti-Amyloid Beta Monoclonal antibody, on
the Progression of Alzheimer’s Disease as Compared to Placebo.” HIC #907005523
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 2-24-10 to 7-1-12
Agency: Bristol-Myers Squibb Company
Title of Grant: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of
the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS708163 in the Treatment of Patients with Prodromal Alzheimer’s Disease.” HIC
#907005506
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 11-4-09 to 12-31-12
Agency: Elan Pharmaceuticals
Title of Grant: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727)
In Patients with Mild to Moderate Alzheimer’s Disease who are apolipoprotein E 4
Non-Carriers (AAB-301)” (includes open-label extension). HIC #801003387 and HIC
#909005759
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $296,075 / $227,750 (est)
Dates of Project: 3-12-08 to 7-1-11
Agency: Elan Pharmaceuticals
Title of Grant: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727)
In Patients with Mild to Moderate Alzheimer’s Disease who are apolipoprotein E 4
Carriers (AAB-302)” (includes open-label extension). HIC #801003388 and HIC
#909005759
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $296,075 / $227,750 (est)
Dates of Project: 3-12-08 to 7-1-11
Agency: Wyeth Research
Title of Grant: A phase IIa, multicenter, randomized, third-party unblinded, adjuvantcontrolled, multiple ascending dose, safety, tolerability and immunogenicity trial of
ACC-001 with QS-21 adjuvant in subjects with mild to moderate Alzheimer’s
disease” (includes open-label extension). HIC # 709003057 and HIC #1009007417
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $308,286 / $237,143 (est)
Dates of Project: 12-12-07 to 7-1-11
13
C. H. van Dyck, M.D.
May 3, 2017
Expired
Agency: Alzheimer’s Association
Grant Number: Investigator-Initiated Research Grant-07-60026
Title of Grant: Amyloid Binding In Subjects At Risk For Alzheimer’s Disease
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $239,965 / $218,151
Dates of Project: 7-1-07 to 6-30-10
Agency: American Health Assistance Foundation
Grant Number: A2004-216
Title of Grant: Nicotinic Receptors in Subjects at Risk for Alzheimer’s
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $99,675 / $99,675
Dates of Project: 4-1-04 to 10-31-06
Agency: Alzheimer’s Association
Grant Number: Investigator-Initiated Research Grant-01-2891
Title of Grant: Serotonergic Correlates of Psychosis in Alzheimer’s Disease
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $239,064 / $217,332
Dates of Project: 5-1-02 to 6-30-07
Agency: National Alliance for Research on Schizophrenia and Affective Disorders
(NARSAD)
Grant Number: Independent Investigator Award
Title of Grant: Serotonergic Correlates of Major Depression in Alzheimer’s Disease
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $99,126 / $91,784
Dates of Project: 7-1-01 to 3-15-07
Agency: NIH/NIMH
Grant Number: 1 R01 MH58620-01A2
Title of Grant: Serotonin 5HT2A Receptors in Depression
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $824,761 / $568,635
Dates of Project: 3-20-00 to 2-28-06
Agency: Ethel F. Donaghue Women’s Health Investigator Program
Grant Number: R05131
Title of Grant: Estrogen & 5-HT2A Receptors in Menopausal Women with Depression
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $49,971 / $49,971
Dates of Project: 7/1/04 to 6/30/06
14
C. H. van Dyck, M.D.
May 3, 2017
Agency: NIH/NIA
Grant Number: 1-UO1-AG024904 (P.I. Michael W. Weiner)
Title of Grant: Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $329,075 / $263,260 (est.)
Dates of Project: 9/30/04 to 8/31/10 (NCE)
Agency: NIH/NIA
Grant Number: 5-U01-AG10483 (P.I. Leon Thal)
Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $500,000 / $400,000 (est.)
Dates of Project: 7-1-01 – 6-30-06
Specific Projects: 1) “Randomized Double-Blind Placebo-Controlled Trial to Evaluate
the Safety and Efficacy of Vitamin E and Donepezil HCl (Aricept®) to Delay Clinical
Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD),”
2) “A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer’s Disease,” 3)
“Assessment Measures for Alzheimer’s Disease Primary Prevention Trials,” 4) “A
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to
Slow the Progression of Alzheimer’s Disease,” 5) “Study of High Dose Supplements
to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer’s
Disease” HIC# 23455
Agency: NIH/NIA
Grant Number: NIH/NIA: 5-U01-AG10483 (P.I. Leon Thal)
Title of Grant: Alzheimer’s Disease Cooperative Study (ADCS) Unit
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
California, San Diego
Total Costs / Total Direct Costs: $300,000 / $240,000 (est.)
Dates of Project: 7-1-96 – 6-30-01
Specific Projects: 1) “A Multicenter, Double-Blind, Placebo-Controlled Study of
Estrogen Replacement Therapy in Patients with Mild to Moderate Alzheimer's
Disease: A Pilot Study of the Alzheimer's Disease Cooperative Study,” 2)
“Multicenter, Placebo-Controlled Trial of Melatonin for Sleep Disturbance in
Alzheimer’s Disease," 3) “Randomized Double-Blind Placebo-Controlled Trial to
Evaluate the Safety and Efficacy of Vitamin E and Donepezil HCl (Aricept®) to
Delay Clinical Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s
Disease (AD),” 4) “A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer’s
Disease.”
Agency: NIH/NIMH
Grant Number: N01-MH90001 (P.I. Jeffrey Lieberman)
Title of Grant: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE);
Comparative Effectiveness of Antipsychotic Medications in Patients with
Alzheimer’s Disease
15
C. H. van Dyck, M.D.
May 3, 2017
Role on Project: Principal Investigator for Yale Site, Sub-Contract with University of
North Carolina
Total Costs / Total Direct Costs: $150,000 / $120,000 (est.)
Dates of Project: 10-1-99 to 9-30-04
Agency: Pfizer, Inc.
Title of Grant: “A Phase 3, multi-center, randomized, double-blind, placebo-controlled
26-week trial to evaluate the efficacy and safety of Dimebon in patients with moderate
to severe Alzheimer’s Disease.” HIC #909005682
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 2-3-10 to 7-1-12
Agency: Bristol-Myers Squibb Company
Title of Grant: “A Multicenter, Randomized Double-Blind Placebo-Controlled Study of
the Safety, tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS708163 in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease.”
HIC#904004964
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 7-7-09 to 5-17-10
Agency: Medivation, Inc.
Title of Grant: “CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled,
Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in
Patients with Mild-to-Moderate Alzheimer’s Disease on Donepezil” (with open-label
extension) HIC #0903004857 and HIC #1010007501
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 7-1-09 to 12-31-11
Agency: Bayer HealthCare Pharmaceuticals, Inc.
Title of Grant: “An open-label, non-randomized, multi-center study to optimize image
assessment and evaluate the efficacy and safety of BA 94-9172 (ZK 6013443) positron
emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients
with probable Alzheimer's disease compared to healthy volunteers.”
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 11-19-2008 to 8-20-09
Agency: Medivation, Inc.
Title of Grant: Connection (DIM14): A Global Phase 3, Double-Blind, PlaceboControlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-ToModerate Alzheimer’s Disease” (with open-label extension) HIC #805003830 and
HIC #901004625
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
16
C. H. van Dyck, M.D.
May 3, 2017
Dates of Project: 7-31-08 to 7-1-11
Agency: Abbott Laboratories
Title of Grant: “A Randomized, Double-Blind, Placebo-Controlled Study Using a
Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in
Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of
Acetylcholinesterase Inhibitors” HIC #711003285
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 7-29-08 to 5-26-09
Agency: Eli Lilly and Company
Title of Grant: Effect of Gamma-Secretase Inhibition on the Progression of Alzheimer’s
Disease: LY450139 versus Placebo (Protocol H6L-MC-LFAN)” (includes open-label
extension. HIC #803003585 and HIC #1002006287
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $ / $ (est)
Dates of Project: 6-1-08 to 7-1-11
Agency: Elan Pharmaceuticals
Title of Grant: A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging,
Safety, and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s disease”
(includes open-label extension) HIC #712003331 and HIC #908005634
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $296,075 / $227,750 (est)
Dates of Project: 3-5-08 to 3-17-10
Agency: GlaxoSmithKline
Title of Grant: A 54-week, double-blind, randomized, placebo-controlled, parallel-group
study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive
therapy to donepezil on cognition and overall clinical response in APOE 4-stratified
subjects with mild to moderate Alzheimer’s disease (REFLECT-2) (includes openlabel extension phase). HIC #608001709, 711003271
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $300,000 / $230,769 (est)
Dates of Project: 11-1-06 to 5-1-09
Agency: Myriad Pharmaceuticals, Inc.
Title of Grant: Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled
Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition,
Activities of Daily Living and Global Function in Subjects with Mild Dementia of
the Alzheimer’s Type.” HIC # 608001710
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $156,000 / $120,000 (est)
Dates of Project: 11-7-06 to 10-20-08
Agency: Myriad Pharmaceuticals, Inc.
17
C. H. van Dyck, M.D.
May 3, 2017
Title of Grant: Phase 3 Multi-center, Randomized, Double Blind, Placebo Controlled
Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition,
Activities of Daily Living and Global Function in Subjects with Mild Dementia of the
Alzheimer’s Type (includes open-label extension phase). HIC #0506000112,
608001770
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $500,000 / $384,615 (est)
Dates of Project: 9-12-05 to 9-12-08
Agency: Elan Pharmaceuticals
Title of Grant: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic,
and Immunogenicity Trial of AAB-001 in Patients with Mild to Moderate
Alzheimer’s Disease (includes open-label extension phase). HIC #27280, 610001937
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $450,000 / $346,154 (est)
Dates of Project: 4-1-05 to 9-30-08
Agency: Eli Lilly and Company
Title of Grant: LY2062430: Multiple-Dose Safety in Subjects with Mild to Moderate
Alzheimer’s Disease and Single-Dose Safety in Healthy Volunteers. HIC
#0601001050
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $422,500 / $325,000 (est)
Dates of Project: 9-1-06 to 9-1-08
Agency: Neurochem, Inc.
Title of Grant: A Phase III Study of the Efficacy and Safety of Alzhemed™ in Patients
with Mild to Moderate Alzheimer’s Disease. HIC #26729
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $675,000 / $519,230 (est)
Dates of Project: 9-1-04 to 7-29-08
Agency: Sanofi-Synthelabo Research
Title of Grant: A randomized, multi-center, double-blind, placebo-controlled, 18-month
study of the efficacy of xaliproden in patients with mild-to-moderate dementia of the
Alzheimer’s type. HIC #25926
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $304,519 / $234,245
Dates of Project: 4-22-04 to 12-31-07
Agency: Eisai Pharmaceuticals
Title of Grant: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled
Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in
Subjects With Mild Cognitive Impairment Sub Study: MRI Test Retest. E2020-A001412. HIC #25925
Role on Project: Principal Investigator
18
C. H. van Dyck, M.D.
May 3, 2017
Total Costs / Total Direct Costs: $361,374 / $277,980
Dates of Project: 3-1-04 to 9-5-07
Agency: Merck Pharmaceuticals
Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the
Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer’s
Disease. HIC #25387
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $481,742 / $370,570
Dates of Project: 12-2-03 to 1-3-06
Agency: Forest Laboratories
Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the
Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of
the Alzheimer’s Type. (01-HIC #23637, 02-HIC #23654, open-label 03-HIC #25388)
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $547,250 / $420,961
Dates of Project: 3-26-03 to 10-13-05
Agency: Pfizer, Inc.
Title of Grant: A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to
Examine the Efficacy of Oral Donepezil (5 mg QD for 6 weeks) after Single Dose and
Steady State Therapy (2 weeks and 6 weeks) in Subjects with Mild Cognitive
Impairment. HIC #25982
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $125,887 / $76,295
Dates of Project: 3-23-04 to 8-24-04
Agency: Mitsubishi Pharma Corporation
Title of Grant: A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the
Safety and Efficacy of MKC-231, 80 mg b.i.d., and 20 mg and 80 mg q.d. in the
Treatment of Mild to Moderate Alzheimer’s Disease. HIC #21975
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $39,566 / $30,435
Dates of Project: 10-17-03 to 10-19-04
Agency: Cortex Pharmaceuticals
Title of Grant: Efficacy and Safety of CX516 (900 mg t.i.d.) In Elderly Participants With
Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group 4-Week Study. HIC #12757
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $128,700 / $99,000
Dates of Project: 4-17-02 to 7-22-03
Agency: Forest Laboratories
19
C. H. van Dyck, M.D.
May 3, 2017
Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the
Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the
Alzheimer’s Type (includes open-label extension phase). HIC #15034
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $477,760 / $367,507
Dates of Project: 6-6-02 to 10-22-04
Agency: Forest Laboratories
Title of Grant: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the
Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of
the Alzheimer’s Type (includes open-label extension phase). HIC
#12379,12380,12381
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $850,262 / $654,047
Dates of Project: 8-6-01 to 3-15-05
Agency: Janssen Pharmaceuticals
Title of Grant: A randomized double blind placebo-controlled trial to evaluate the
efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI)
clinically at risk for development of clinically probable Alzheimer’s disease (includes
open-label extension phase). HIC #12222, 25095
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $329,140 / $253,185
Dates of Project: 6-27-01 to 4-7-04
Agency: Eisai Pharmaceuticals
Title of Grant: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled
Evaluation of The Safety and Efficacy of Donepezil Hydrochloride (E2020) In
Patients With Severe Alzheimer’s Disease Followed by a 12 Week Open-Label
Extension Period. HIC #12165
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $10,641 / $8,185
Dates of Project: 6-15-01 to 10-29-02
Agency: Neotherapeutics, Inc.
Title of Grant: A Placebo-Controlled Dose-Titration Efficacy and Tolerability Study of
Neotrofin in Patients with Probable Alzheimer’s Disease. HIC #12309
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $317,854 / $244,503
Dates of Project: 4-23-01 to 2-13-02
Agency: Janssen Pharmaceuticals
Title of Grant: Placebo Controlled Evaluation of Galantamine in the Treatment of
Alzheimer’s disease: Safety and Efficacy of a Controlled Release Formulation
(includes open-label extension phase). HIC #12090, 12632
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $178,590 / $137,377
20
C. H. van Dyck, M.D.
May 3, 2017
Dates of Project: 3-12-01 to 7-7-03
Agency: Merck Pharmaceuticals
Title of Grant: The Safety and Efficacy of MK-0966 25mg in Delaying the Progression of
the Symptoms of Alzheimer's Disease in Patients with Probable AD (MK-126). HIC
#11634
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $254,758 / $195,968
Dates of Project: 5-24-00 to 6-1-01
Agency: Cephalon, Inc.
Title of Grant: A 6-Week, Double-Blind, Randomized, Placebo-Controlled, ParallelGroup Study to Evaluate the Safety and Efficacy of Provigil (Modafinil)
Administered as Single Oral Doses of 100 mg/d and 400 mg/d (Phase A) and 200
mg/d (Phase B) in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD),
followed by an 8-Week Open-Label Extension. HIC #11646
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $104,364 / $80,280
Dates of Project: 3-28-00 to 11-1-00
Agency: Eli Lilly and Company
Title of Grant: Olanzapine Versus Risperidone or Placebo in the Treatment of Psychosis
and Associated Behavioral Disturbances in Patients with Dementia. HIC #10610
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $187,731 / $144,409
Dates of Project: Dates of Award: 2-24-99 to 8-7-01
Agency: Merck Pharmaceuticals
Title of Grant: The Safety and Efficacy of MK-0966 in Slowing the Progression of the
Symptoms of Alzheimer's Disease (MK-091). HIC #10668
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $471,666 / $362,820
Dates of Project: 2-22-99 to 11-15-00
Agency: Janssen Pharmaceuticals
Title of Grant: Placebo controlled evaluation of galantamine in the treatment of
Alzheimer’s Disease: Safety and efficacy under a slow-titration regimen (includes
open-label extension phase). HIC #10535, 10964, 11589
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $427,825 / $329,096
Dates of Project: 11-20-98 to 8-8-01
Agency: Takeda America Pharmaceuticals
Title of Grant: A Randomized Double-Blind, Placebo Controlled, 12-Month Safety and
Efficacy Trial of Idebenone (CV-2619) 360 mg tid in Patients with Probable
Alzheimer's Disease. HIC #10097, 10098
Role on Project: Principal Investigator
21
C. H. van Dyck, M.D.
May 3, 2017
Total Costs / Total Direct Costs: $578,626 / $445,097
Dates of Project: 4-13-98 to 3-25-99
Agency: Novartis Pharmaceuticals Corp.
Title of Grant: An Open Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d.
(3 mg/day) through 6 mg b.i.d. (12 mg/day) of Exelon™ in Patients with Mild to
Severe Probable Alzheimer’s Disease in the Community Setting. HIC #9561
Role on Project: Principal Investigator
Percent Effort: 5%
Total Costs / Total Direct Costs: $365,061 / $280,816
Dates of Project: 7-15-97 to 6-2-00
Agency: Parke-Davis, Inc.
Title of Grant: A 52 Week, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup, Multicenter Study of Milameline (CI-979/RU 35926) in Patients with
Probable Alzheimer’s Disease with Long-Term Open-Label Extension
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $92,956 / $71,505
Dates of Project: 9-1-96 to 10-1-97
Agency: Eisai America, Inc.
Title of Grant: A 54 Week, Randomized, Double-Blind, Placebo-Controlled Evaluation
of the Effects of Donepezil Hydrochloride (E2020) on Functional Outcomes in
Patients with Alzheimer’s Disease with a Staged Crossover to Open-Label Donepezil
Hydrochloride (E2020) Treatment
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $10,000 / $7,692
Dates of Project: 7-1-96 to 7-1-97
Agency: Mediolanum Pharmaceuticals
Title of Grant: A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Efficacy
Study of Eptastigmine Following Four-Week, Step-Wise Dose Escalations in Patients
with Probable Alzheimer’s Disease
Role on Project: Principal Investigator (Also Principal Investigator of multicenter SPECT
trial examining the effects of Eptastigmine on regional cerebral blood flow in 72
Alzheimer's disease patients)
Total Costs / Total Direct Costs: $522,164 / $401,665
Dates of Project: 7-1-96 to 1-1-98
Agency: American Federation for Aging Research (AFAR)
Title of Grant: Motor Correlates of Striatal Dopamine Transporter Binding with [123I]ßCIT SPECT in Older Adults
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $40,000 / $40,000
Dates of Project: 7-1-95 to 12-31-96
Agency: Forest Laboratories
22
C. H. van Dyck, M.D.
May 3, 2017
Title of Grant: Clinical Evaluation of the Safety and Efficacy of AF102B vs. Placebo in
the Treatment of Patients with Dementia of the Alzheimer's Type
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $332,371 / $255,670
Dates of Project: 1-1-95 to 10-1-97
Agency: Glaxo, Inc.
Title of Grant: A Controlled Study of Ondansetron in the Treatment of Primary
Degenerative Dementia of the Alzheimer's Type
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $110,000 / $84,615
Dates of Project: 12-1-93 to 4-1-95
Agency: Forest Laboratories
Title of Grant: Efficacy of Extended-Release Oral Physostigmine in Alzheimer's Disease
and Senile Dementia of the Alzheimer Type
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $504,500 / $388,077
Dates of Project: 6-1-93 to 7-1-97
Agency: DuPont Merck Pharmaceuticals, Inc.
Title of Grant: Evaluation of Tc-99m Bicisate in Healthy Elderly Volunteers and Patients
with Mild to Moderate Dementia of the Alzheimer's Type
Role on Project: Principal Investigator (also Principal Investigator of multicenter SPECT
trial examining the effects of Linopirdine on regional cerebral blood flow in 80
Alzheimer's disease patients)
Total Costs / Total Direct Costs: $280,000 / $215,385
Dates of Project: 7-1-92 to 7-31-94
Agency: NIMH
Grant Number: 1 R03 MH47459-01A1
Title of Grant: Comparison of IMP & HMPAO Cerebral SPECT Images in Alzheimer's
Disease
Role on Project: Principal Investigator
Total Costs / Total Direct Costs: $84,000 / $50,000
Dates of Project: 9-15-91 to 8-31-93
23
C. H. van Dyck, M.D.
May 3, 2017
Bibliography:
Original Articles
1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI: Clarifying
confusion: The Confusion Assessment Method (CAM). A new method for detection of
delirium. Ann Intern Med 1991; 113(12):941-948.
2. Rosen MI, Bridge TP, O'Malley SS, Pearsall HR, Martini BL, O'Connor PG, BrettSmith H, Thomas HM, van Dyck CH, Woods SW, Kosten TR: Peptide T treatment of
cognitive impairment in HIV+ intravenous drug users. Am J Addictions 1992;1(3):1-7.
3. Laruelle M, van Dyck CH, Abi-Dargham A, Zea-Ponce Y, Zoghbi SS, Charney DS,
Baldwin RM, Hoffer PB, Kung HF, Innis RB: Compartmental modeling of [123I]IBF
binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994;35:743-754.
4. van Dyck CH, Rosen MI, Thomas HM, McMahon TJ, Wallace EA, O'Connor PG,
Sullivan M, Krystal JH, Hoffer PB, Woods SW, Kosten TR: SPECT regional cerebral
blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine.
Psychiatry Res Neuroimaging 1994;55:181-191.
5. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CH, Price LH,
Zubal G, Hoffer PB, Charney DS: Opiate dependence and withdrawal: Preliminary
assessment using single photon emission computerized tomography (SPECT). Am J Drug
Alcohol Abuse 1995;21:47-63.
6. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce
Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in striatal
dopamine transporter binding with Iodine-123-ß-CIT SPECT. J Nucl Med 1995;36:11751181.
7. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS,
Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB: SPECT imaging of striatal
dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-1190.
8. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Price LH, Leckman
JF, Innis RB: [123I]ß-CIT SPECT imaging demonstrates increased striatal dopamine
transporter binding in Tourette's syndrome. Am J Psychiatry 1995;152:1359-1361.
9. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi SS, Zea-Ponce Y, Baldwin RM,
Fussell B, Smith EO, Charney DS, van Dyck CH, Hoffer PB, Innis RB: Decreased singlephoton emission computed tomographic [123I]ß-CIT striatal uptake correlates with
symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598. (Correction of
authorship list. Ann Neurol 1996;39:417.)
24
C. H. van Dyck, M.D.
May 3, 2017
10. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS,
van Dyck CH, Hoffer PB, Innis RB: [123I]ß-CIT SPECT imaging demonstrates bilateral
loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
11. van Dyck CH, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Zea-Ponce Y, Charney
DS, Hoffer PB, Innis RB: Human biodistribution and dosimetry of the SPECT D2
dopamine receptor radioligand [123I]IBF. Nucl Med Biol 1996;23:9-15.
12. Wallace EA, Wisniewski G, Zubal G, van Dyck CH, Pfau SE, Smith EO, Rosen MI,
Sullivan MC, Woods SW, Kosten TR: Acute cocaine effects on absolute cerebral blood
flow. Psychopharmacology 1996;128:17-20.
13. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi SS, Zea-Ponce
Y, Neumeyer J, Charney DS, Hoffer PB, Innis RB: Reproducibility of iodine-123-ß-CIT
SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-228.
14. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza C, Erdos J, McCanceKatz E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal J, Charney
DS, Innis RB: SPECT imaging of amphetamine-induced dopamine activity in drug free
schizophrenic subjects. Proc Natl Acad Sci 1996;93:9235-9240. PMCID: PMC38625.
15. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M,
Bennett A, Delaney R, Bronen R, Hoffer PB: Comparison of technetium-99m-HMPAO
and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. J Nucl Med
1996;37(11):1749-1755.
16. Arnsten AFT, Lin CH, van Dyck CH, Stanhope KJ: The effects of 5-HT3 receptor
antagonists on cognitive performance in aged monkeys. Neurobiol Aging 1997;18:21-28.
17. van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Lin CH, Pearsall
HR, Woods SW, Kosten TR: Sustained-release methylphenidate for cognitive impairment
in HIV-1–infected drug abusers: A pilot study. J Neuropsychiatry Clin Neurosci
1997;9:29-36.
18. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, Arnsten AFT,
Hoffer PB: The acetylcholine releaser linopirdine increases parietal regional cerebral
blood flow in Alzheimer's disease. Psychopharmacology 1997;132(3):217-226.
19. Seibyl JP, Marek KL, Sheff K, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Charney DS,
Henry, E, van Dyck CH, Hoffer PB, Innis RB: Test/retest reproducibility of [123I]ß-CIT
SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med
1997;38:1453-1459.
20. Gelernter J, van Dyck CH, van Kammen DP, Malison R, Price LH, Cubells JF,
Berman R, Charney DS, and Heninger G: Ciliary neurotrophic factor null allele
frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med
Genet B Neuropsychiatr Genet 1997;74:497-500.
25
C. H. van Dyck, M.D.
May 3, 2017
21. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH,
Charney DS, Innis RB, Laruelle M: Increased striatal dopamine transmission in
schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-767.
22. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin
RM, Seibyl JP, Price LH, Kosten TR, Innis RB: Elevated striatal dopamine transporters
during acute cocaine abstinence as measured by [123I]ßCIT SPECT. Am J Psychiatry
1998;155:832-834.
23. Seibyl JP, Marek KL, Sheff K, Zoghbi SS, Baldwin RM, Charney DS, van Dyck CH,
Innis RB: Iodine-123-ß-CIT and iodine-123-FPCIT SPECT measurement of dopamine
transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-1508.
24. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden M, Okereke O, Varma
P, Seibyl JP, Hoffer PB: The absence of an apolipoprotein E 4 allele is associated with
increased parietal rCBF asymmetry in Alzheimer's disease. Arch Neurol 1998;55:14601466.
25. Malison RT, Price LH, Berman RM, van Dyck CH, Pelton GH, Carpenter LL,
Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB,
Charney DS: Reduced brain serotonin transporter availability in major depression as
measured by [123I]-2ß-carbomethoxy-3ß–(4-iodophenyl)tropane and single photon
emission computed tomography. Biol Psychiatry 1998;44:1090-1098.
26. Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ, and The
Eptastigmine Study Group (includes van Dyck CH): Efficacy and safety of eptastigmine
for the treatment of patients with Alzheimer’s disease. Neurology 1999;52:700-708.
27. Tan P-Z, Baldwin RM, van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS,
Innis RB: Characterization of radioactive metabolites of 5-HT2A receptor PET ligand
[18F]altanserin in human and rodent. Nucl Med Biol 1999;26:601-608.
28. Verhoeff NPLG, Soares JC, D’Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi
SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB:
[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res
Neuroimaging 1999;91:163-173.
29. van Dyck CH, Newhouse P, Falk WE, Mattes JA: Extended-release physostigmine in
Alzheimer's disease: a multicenter, double-blind, 12-week study with dose-enrichment.
Arch Gen Psychiatry 2000;57:157-164.
30. van Dyck CH, Tan P-Z, Baldwin RM, Amici LA, Garg PK, Ng CK, Soufer R,
Charney DS, Innis RB: PET quantification of 5-HT2A receptors in the human brain: a
constant infusion paradigm with [18F]altanserin. J Nucl Med 2000;41:234-241.
26
C. H. van Dyck, M.D.
May 3, 2017
31. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E,
Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ: Estrogen replacement
therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled
trial. JAMA 2000;283:1007-1015.
32. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza C, Krystal JH, Seibyl JP,
Baldwin RM, Innis RB: Dopamine and serotonin transporters in patients with
schizophrenia: an imaging study with [123I]ß-CIT SPECT. Biol Psychiatry 2000;47:371379.
33. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, Baldwin
RM, Innis RB: Age-related decline in central serotonin transporter availability with
[123I]ß-CIT SPECT. Neurobiol Aging 2000;21:497-501.
34. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the
Galantamine USA-10 Study Group (includes van Dyck CH): A-5-month, randomized,
placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276.
35. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT: The alpha-2Aadrenoceptor agonist, guanfacine increases regional cerebral blood flow in dorsolateral
prefrontal cortex of monkeys performing a spatial working memory task.
Neuropsychopharmacology 2000;23:240-249.
36. van Dyck CH, Soares J, Tan P-Z, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK,
Seibyl JP, Charney DS, Innis RB: Equilibrium modeling of 5-HT2A receptors with
[18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med
Biol 2000;27:715-722.
37. van Dyck CH: Neuroimaging in Alzheimer’s disease: Relevance for treatment.
Current Psychiatry Reports 2001;3:13-19.
38. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB, and
Laruelle M: The variable number of tandem repeats polymorphism of the dopamine
transporter gene is not associated with significant chance in dopamine transporter
phenotype in humans. Neuropsychopharmacology 2001;24:553-560.
39. Soares JC, van Dyck CH, Tan P-Z, Zoghbi SS, Garg P, Soufer R, Baldwin RM, Fujita
M, Staley JK, Fu X, Amici LA, Seibyl J, Innis RB: Reproducibility of in vivo brain
measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Res
Neuroimaging 2001;106:81-93.
40. Staley JK, van Dyck CH, Tan P, Al-Tikriti M, Ramsby Q, Klump H, Ng C, Garg P,
Soufer R, Baldwin R, Innis RB: Comparison of [18F]altanserin and [18F]deuteroaltanserin
for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies.
Nucl Med Biol 2001;28: 271-279.
27
C. H. van Dyck, M.D.
May 3, 2017
41. Marek KL, Innis RB, van Dyck CH, Fussell B, Early M, Eberly S, Oakes D, Seibyl
JP: [123I]ß-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression.
Neurology 2001;57:2089-2094.
42. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis
RB: Age-related decline in dopamine transporters: Analysis of striatal subregions,
nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43.
43. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM,
Seibyl JP, Innis RB: Unaltered dopamine transporter availability in adult attention deficit
hyperactivity disorder. Am J Psychiatry 2002;159(2):309-312.
44. Grundman M, Sencakova D, Jack CR Jr, Petersen RC, Kim HT, Schultz A, Weiner
MF, DeCarli C, DeKosky ST, van Dyck CH, Thomas RG, Thal LJ; Alzheimer's Disease
Cooperative Study: Brain MRI hippocampal volume and prediction of clinical status in a
mild cognitive impairment trial. J Mol Neurosci 2002;19:23-27.
45. Lappalainen J, Kranzler HR, Malison R, Price LH, van Dyck CH, Rosenheck RA,
Cramer J, Southwick S, Charney DS, Krystal JK, Gelernter J: A functional neuropeptide
Y Leu7Pro polymorphism associated with alcohol dependence in a large population
sample from the United States. Arch Gen Psychiatry 2002;59:825-831.
46. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg
PK, Seibyl JP, Innis RB. Increase in prefrontal cortex serotonin2A receptors following
estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160(8):1522-1524.
47. Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF,
DeCarli C, DeKosky ST, van Dyck CH, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas
RG, Thal LJ. Hippocampal volume is associated with memory but not nonmemory
cognitive performance in patients with mild cognitive impairment. J Mol Neurosci
2003;20(3):241-248.
48. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A,
Seneca N, Tipre D, DeNucci CC, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS,
London ED, Seibyl JP, Baldwin RM, Innis RB. Quantification of nicotinic acetylcholine
receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging
2003;30:1620-1629.
49. van Dyck, CH. Understanding the latest advances in pharmacologic interventions for
Alzheimer's disease. CNS Spectr 2004;9(7 Suppl 5):24-28.
50. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster
NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin
S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, CahnWeiner D, Thal LJ, and the Alzheimer’s Disease Cooperative Study. Mild Cognitive
Impairment can be distinguished from Alzheimer disease and normal aging for clinical
trials. Arch Neurol 2004;61(1):59-66.
28
C. H. van Dyck, M.D.
May 3, 2017
51. van Dyck, CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, Baldwin
RM, Innis RB, Gelernter J. Central serotonin transporter availability measured with
[123I]ß-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry
2004;161(3):525-531.
52. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, van
Dyck CH, Baldwin RM, Seibyl JP, Charney DS, Innis RB. Brain serotonin transporter
availability predicts treatment response to selective serotonin reuptake inhibitors. Biol
Psychiatry 2004;56(7):497-502.
53. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D,
Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal, LJ. Vitamin E and
donepezil for the treatment of Mild Cognitive Impairment. N Engl J Med
2005;352(23):2379-2388.
54. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin
RM, Innis RB, Gelernter J. Increased dopamine transporter availability associated with
the 9-repeat allele of SLC6A3 gene. J Nucl Med 2005;46 745-751.
55. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH,
Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ;
Alzheimer's Disease Cooperative Study. Sex, apolipoprotein E epsilon4 status, and
hippocampal volume in mild cognitive impairment. Arch Neurol 2005, 62(6):953-7.
56. Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow
P, Verhoeff NPLG, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl
JP, Innis RB, Krystal JH. Cortical -aminobutyric acid type A-benzodiazepine receptors
in recovery from alcohol dependence: relationship to features of alcohol dependence and
cigarette smoking. Arch Gen Psychiatry 2005, 62;877-888.
57. Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD,
Riccardi P, Mitsis E, Seibyl JP. 123I-5-IA-85380 SPECT measurement of nicotinic
acetylcholine receptors in human brain by the constant infusion paradigm: Feasibility and
reproducibility. J Nucl Med 2005;46:1466-1472.
58. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JP,
Innis RB, van Dyck CH. Striatal dopamine transporter availability with [123I]ß-CIT
SPECT is unrelated to gender or menstrual cycle. Psychopharmacology 2005;183(2):181189.
59. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M,
Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: Research and
development of a peptide derived from activity-dependent neuroprotective protein
(ADNP). CNS Drug Rev 2005;11(4):353-368.
29
C. H. van Dyck, M.D.
May 3, 2017
60. van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in
Alzheimer's disease patients maintained on donepezil. Am J Geriatr Psychiatry 2006;
14(5):428-437.
61. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, MacAvoy M,
Gelernter J, van Dyck CH. Apolipoprotein E 4 allele is unrelated to cognitive or
functional decline in Alzheimer’s disease: retrospective and prospective analysis. Dement
Geriatr Cogn Disord 2006;22(1):73-82.
62. Basso M, Yang J, Warren L, MacAvoy MG, Varma P, Bronen RA, van Dyck CH.
Volumetry of amygdala and hippocampus and memory performance in Alzheimer’s
disease. Psychiatry Res Neuroimaging 2006;146(3):251-261.
63. Zuo L, van Dyck CH, Luo X, Kranzler HR, Yang BZ, Gelernter J. Variation at APOE
and STH loci and Alzheimer's disease. Behav Brain Funct 2006;2:13. PMCID:
PMC1526745.
64. Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, Price
LH, Southwick S, Yang BZ, Rasmussen A, Gelernter J. Brain derived neurotrophic factor
(BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress
disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr
Genet 2006;141(4):387-393. PMCID: PMC2567822.
65. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin
JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR,
London ED, O’Malley S, van Dyck CH. Human tobacco smokers in early abstinence have
higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci
2006;26(34):8707-8714.
66. Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH.
Apolipoprotein E 4 is associated with atrophy of the amygdala in Alzheimer's disease.
Neurobiol Aging 2006;27(10):1416-1424.
67. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. 2A-Adrenoceptor
stimulation improves prefrontal cortical regulation of behavior through inhibition of
cAMP signaling in aging animals. Learn Mem 2006;13(6):770-776. PMCID:
PMC1783631.
68. Schmitt FA, van Dyck CH, Wichems CH, Olin JT. Cognitive response to memantine
in moderate to severe Alzheimer disease patients already receiving donepezil: An
exploratory reanalysis. Alzheimer Dis Assoc Disord 2006;20(4):255-262.
69. Zdanys KF , Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman
KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E 4 allele increases risk for
psychotic symptoms in Alzheimer’s disease. Neuropsychopharmacology 2007;32(1):171179.
30
C. H. van Dyck, M.D.
May 3, 2017
70. Mitsis EM, Cosgrove KP, Staley JK, Frohlich EB, Bois F, Tamagnan GD, Estok KM,
Seibyl JP, van Dyck CH. [123I]5-IA-85380 SPECT imaging of ß2-nicotinic acetylcholine
receptor availability in the aging human brain. Ann NY Acad Sci 2007;1097:168-170.
71. Tampi RR, van Dyck CH. Memantine: Efficacy and safety in mild-to-severe
Alzheimer's disease. Neuropsychiatric Disease and Treatment 2007;3(2):245-258.
72. van Dyck CH, Tariot PN, Meyers B, Resnick EM; for the Memantine MEM-MD-01
Study Group. A 24-week randomized, controlled trial of memantine in patients with
moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2):136-143.
73. Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E,
Maciejewski PK, Epperson CN, Allen S, O’Malley S, Mazure CM, Seibyl JP, van Dyck
CH, Staley JK. [123I]5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor
availability in nonsmokers: Effects of sex and menstrual cycle phase. J Nucl Med
2007;48:1633-1640.
74. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study
Group (includes van Dyck CH). Memantine treatment in patients with mild to moderate
Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, doubleblind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-89.
75. Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. The views
of AD patients and their study partners on proxy consent for clinical trial enrollment. Am
J Geriatr Psychiatry 2008;16(3):240-247.
76. van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM,
Seibyl JP, Innis RB, Arnsten AFT. Striatal dopamine transporters correlate with simple
reaction time in elderly subjects. Neurobiol Aging 2008;29(8):1237-1246. Epub 2007
Mar 23.
77. Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. Interpreting
the clinical significance of capacity scores for informed consent in Alzheimer disease
clinical trials. Am J Geriatr Psychiatry 2008;16(7):568-574. Epub 2008 Jun 12.
78. Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D,
Doody RS, Thal LJ; Members of the Alzheimer's Disease Cooperative Study (ADCS)
(includes van Dyck CH). Longitudinal MRI findings from the vitamin E and donepezil
treatment study for MCI. Neurobiol Aging 2008;29(9):1285-1295. PMCID:
PMC2768818.
79. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF,
Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative
Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease:
a randomized controlled trial. JAMA 2008;300(15):1774-1783. PMCID: PMC2684821.
31
C. H. van Dyck, M.D.
May 3, 2017
80. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; On behalf of the
MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: No clinical
effect on AD progression in a randomized trial. Neurology 2008;71(21):1702-1708.
81. van Dyck CH. Imaging microglial activation in Alzheimer's disease: What does it
mean? Biol Psychiatry 2008;64(10):833-834.
82. van Dyck CH, Lyness JM, Rohrbaugh RM, Siegal AP. Cognitive and psychiatric
effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing
home study. Int Psychogeriatr 2009;21(1):138-147.
83. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe
RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative
(includes van Dyck CH). Episodic memory loss is related to hippocampal-mediated betaamyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-1323. PMCID:
PMC2677792.
84. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung
MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Serial PIB and MRI in normal, mild
cognitive impairment and Alzheimer's disease: implications for sequence of pathological
events in Alzheimer's disease. Brain. 2009 May;132(Pt 5):1355-65. PMCID:
PMC2677798.
85. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's
Disease Cooperative Study Group (includes van Dyck CH). Donepezil delays progression
to AD in MCI subjects with depressive symptoms. Neurology 2009;72(24):2115-2121.
86. Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, Estok KM,
Seibyl JP, van Dyck CH. Age-related decline in nicotinic receptor availability with
[123I]5-IA-85380 SPECT. Neurobiol Aging 2009 Sep;30(9):1490-1497. Epub 2008 Feb 1.
87. Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK,
van Dyck CH. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer
disease and mild cognitive impairment. J Nucl Med 2009;50:1455-1463.
88. Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM,
MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates
of 5-HT2A receptors in Alzheimer’s disease with [18F]deuteroaltanserin and PET.
Psychiatry Res Neuroimaging 2009;173(3):212-217.
89. Zdanys KF, Kleiman TG, Zhang H, Ozbay F, MacAvoy MG, Gelernter J, van Dyck
CH. BDNF variants, premorbid educational attainment, and disease characteristics in
Alzheimer’s disease: An exploratory study. J Alzheimers Dis 2009;17(4):887-98.
32
C. H. van Dyck, M.D.
May 3, 2017
90. Hains AB, Vu MAT, Maciejewski PK, van Dyck CH, Gottron M, Arnsten AFT.
Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and
cognition from the effects of chronic stress. Proc Natl Acad Sci 2009;106(42):17957-62.
91. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M,
Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg
I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of
bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-70.
92. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM; the Alzheimer's
Disease Neuroimaging Initiative (includes van Dyck CH). Subregional neuroanatomical
change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci 2009;106(49):2095420959.
93. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH;
Tarenflurbil Phase 3 Study Group (includes van Dyck CH). Effect of tarenflurbil on
cognitive decline and activities of daily living in patients with mild Alzheimer disease: a
randomized controlled trial. JAMA 2009;302(23):2557-64.
94. Rimol LM, Agartz I, Djurovic S, Brown AA, Roddey JC, Kähler AK, Mattingsdal M,
Athanasiu L, Joyner AH, Schork NJ, Halgren E, Sundet K, Melle I, Dale AM,
Andreassen OA; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH).
Sex-dependent association of common variants of microcephaly genes with brain
structure. Proc Natl Acad Sci 2010 Jan 5;107(1):384-8.
95. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz
N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR
Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (includes van
Dyck CH). Whole genome association study of brain-wide imaging phenotypes for
identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort.
Neuroimage. 2010 Nov 15;53(3):1051-63.
96. Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A;
Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). A robust method
to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage
2010;50(4):1427-37.
97. Stein JL, Hua X, Lee S, Ho AJ, Leow AD, Toga AW, Saykin AJ, Shen L, Foroud T,
Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Dechairo
BM, Potkin SG, Weiner MW, Thompson P; Alzheimer's Disease Neuroimaging Initiative
(includes van Dyck CH). Voxelwise genome-wide association study (vGWAS).
Neuroimage. 2010 Nov 15;53(3):1160-74.
98. Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, Dinov ID, Toga AW, Saykin
AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN,
Corneveaux JJ, Stephan DA, DeCarli CS, DeChairo BM, Potkin SG, Jack CR Jr, Weiner
MW, Raji CA, Lopez OL, Becker JT, Carmichael OT, Thompson PM; Alzheimer's
33
C. H. van Dyck, M.D.
May 3, 2017
Disease Neuroimaging Initiative (includes van Dyck CH). A commonly carried allele of
the obesity-related FTO gene is associated with reduced brain volume in the healthy
elderly. Proc Natl Acad Sci 2010 May 4;107(18):8404-9.
99. Wolk DA, Dickerson BC; the Alzheimer's Disease Neuroimaging Initiative (includes
van Dyck CH). Apolipoprotein E (APOE) genotype has dissociable effects on memory
and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci
2010 Jun 1;107(22):10256-61.
100. Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, Jiang T; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Effects of BDNF Val66Met
polymorphism on brain metabolism in Alzheimer's disease. Neuroreport 2010 Aug
23;21(12):802-7.
101. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC; Alzheimer's
Disease Neuroimaging Initiative investigators (includes van Dyck CH). Reduced sample
sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol
Aging 2010 Aug;31(8):1452-62.
102. Vounou M, Nichols TE, Montana G; Alzheimer's Disease Neuroimaging Initiative
(includes van Dyck CH). Discovering genetic associations with high-dimensional
neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage. 2010
Nov 15;53(3):1147-59.
103. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH,
Malison RT, Carson RE, Ding YS. Clinically relevant doses of methylphenidate
significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010
Nov 1;68(9):854-60.
104. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, van Dyck CH,
Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Docosahexaenoic Acid
supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA
2010 Nov 3;304(17):1903-11.
105. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM,
Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS,
Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative
(includes van Dyck CH). Genome-wide association study of CSF biomarkers Abeta1-42,
t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011 Jan 4;76(1):69-79.
106. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, Jack
CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck
CH). Identifying cognitively healthy elderly individuals with subsequent memory decline
by using automated MR temporoparietal volumes. Radiology. 2011 Jun;259(3):844-51.
Epub 2011 Apr 5.
34
C. H. van Dyck, M.D.
May 3, 2017
107. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F,
Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group (includes
van Dyck CH). Cerebral amyloid-β PET with florbetaben (18F) in patients with
Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet
Neurol. 2011 May;10(5):424-35. Epub 2011 Apr 8.
108. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry
M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve
cognition or global function when used as adjunctive therapy to AChE inhibitors in mildto-moderate Alzheimer's disease: Two Phase 3 studies. Curr Alzheimer Res. 2011 Aug
1;8(5):592-606.
109. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner
MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH).
Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011
Oct;68(10):1257-66. Epub 2011 Jun 13.
110. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS.
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer
disease. Neurology. 2011 Aug 9;77(6):556-63. Epub 2011 Jul 27.
111. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN,
Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M.
Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in
mild to moderate Alzheimer disease. Neurology 2011 Sep 27;77(13):1253-1262.
112. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Predicting MCI outcome with clinically
available MRI and CSF biomarkers. Neurology. 2011 Oct 25;77(17):1619-28. Epub 2011
Oct 12.
113. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen
H, Lötjönen J; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH).
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS
One. 2011;6(10):e25446. Epub 2011 Oct 13.
114. Mattila J, Koikkalainen J, Virkki A, van Gils M, Lötjönen J; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Design and application of a generic
clinical decision support system for multiscale data. IEEE Trans Biomed Eng 2012
Jan;59(1):234-40. Epub 2011 Oct 10.
115. Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging
Initiative (includes van Dyck CH). Alzheimer disease biomarkers are associated with
body mass index. Neurology. 2011 Nov 22;77(21):1913-20.
35
C. H. van Dyck, M.D.
May 3, 2017
116. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative (includes
van Dyck CH). MRI cortical thickness biomarker predicts AD-like CSF and cognitive
decline in normal adults. Neurology. 2012 Jan 10;78(2):84-90. Epub 2011 Dec 21.
117. Chu C, Hsu AL, Chou KH, Bandettini P, Lin C; Alzheimer's Disease Neuroimaging
Initiative (includes van Dyck CH). Does feature selection improve classification
accuracy? Impact of sample size and feature selection on classification using anatomical
magnetic resonance images. Neuroimage. 2012 Mar;60(1):59-70. Epub 2011 Dec 1.
118. Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT,
Macciardi F, Potkin SG; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck
CH). Empirical derivation of the reference region for computing diagnostic sensitive
¹⁸ fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.
Biochim Biophys Acta. 2012 Mar;1822(3):457-66. Epub 2011 Sep 19.
119. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey
BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN,
Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I,
Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative;
Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R,
Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ,
Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D,
Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P,
Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen
K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka
M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder
PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann
BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS,
Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B,
Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman
H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts
P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S,
Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith
CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein
BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz
C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, MartinCook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow
RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F,
Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE,
MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C,
Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D,
Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N,
Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA,
Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg
J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A,
Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P,
36
C. H. van Dyck, M.D.
May 3, 2017
Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S,
Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S,
Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D,
Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM,
Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S,
Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E,
Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y,
Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B,
Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M,
Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D,
Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Association of common genetic
variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl
Acad Sci U S A. 2012 Mar 6;109(10):3985-90. Epub 2012 Feb 16.
120. Koikkalainen J, Pölönen H, Mattila J, van Gils M, Soininen H, Lötjönen J;
Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH). Improved
classification of Alzheimer's disease data via removal of nuisance variability.
PLoS One. 2012;7(2):e31112. Epub 2012 Feb 13.
121. Johnstone D, Milward EA, Berretta R, Moscato P; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Multivariate protein signatures of preclinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI)
plasma proteome dataset. PLoS One. 2012;7(4):e34341. Epub 2012 Apr 2.
122. Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck
CH). Predicting missing biomarker data in a longitudinal study of Alzheimer disease.
Neurology. 2012 May 1;78(18):1376-82. Epub 2012 Apr 4.
123. Yuan L, Wang Y, Thompson PM, Narayan VA, Ye J; Alzheimer's Disease
Neuroimaging Initiative (includes van Dyck CH). Multi-source feature learning for joint
analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage. 2012 Jul
2;61(3):622-32. Epub 2012 Mar 29.
124. Silver M, Montana G; Alzheimer's Disease Neuroimaging Initiative (includes van
Dyck CH). Fast identification of biological pathways associated with a quantitative trait
using group lasso with overlaps. Stat Appl Genet Mol Biol. 2012 Jan 6;11(1):Article 7.
doi: 10.2202/1544-6115.1755.
125. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, Toro R,
Appel K, Bartecek R, Bergmann Ø, Bernard M, Brown AA, Cannon DM, Chakravarty
MM, Christoforou A, Domin M, Grimm O, Hollinshead M, Holmes AJ, Homuth G,
Hottenga JJ, Langan C, Lopez LM, Hansell NK, Hwang KS, Kim S, Laje G, Lee PH, Liu
X, Loth E, Lourdusamy A, Mattingsdal M, Mohnke S, Maniega SM, Nho K, Nugent AC,
O'Brien C, Papmeyer M, Pütz B, Ramasamy A, Rasmussen J, Rijpkema M, Risacher SL,
Roddey JC, Rose EJ, Ryten M, Shen L, Sprooten E, Strengman E, Teumer A, Trabzuni
D, Turner J, van Eijk K, van Erp TG, van Tol MJ, Wittfeld K, Wolf C, Woudstra S,
37
C. H. van Dyck, M.D.
May 3, 2017
Aleman A, Alhusaini S, Almasy L, Binder EB, Brohawn DG, Cantor RM, Carless MA,
Corvin A, Czisch M, Curran JE, Davies G, de Almeida MA, Delanty N, Depondt C,
Duggirala R, Dyer TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill M, Göring HH,
Hagler DJ, Hoehn D, Holsboer F, Hoogman M, Hosten N, Jahanshad N, Johnson MP,
Kasperaviciute D, Kent JW Jr, Kochunov P, Lancaster JL, Lawrie SM, Liewald DC,
Mandl R, Matarin M, Mattheisen M, Meisenzahl E, Melle I, Moses EK, Mühleisen TW,
Nauck M, Nöthen MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Reinvang I, Rentería
ME, Rietschel M, Roffman JL, Royle NA, Rujescu D, Savitz J, Schnack HG, Schnell K,
Seiferth N, Smith C, Steen VM, Valdés Hernández MC, Van den Heuvel M, van der Wee
NJ, Van Haren NE, Veltman JA, Völzke H, Walker R, Westlye LT, Whelan CD, Agartz
I, Boomsma DI, Cavalleri GL, Dale AM, Djurovic S, Drevets WC, Hagoort P, Hall J,
Heinz A, Jack CR Jr, Foroud TM, Le Hellard S, Macciardi F, Montgomery GW, Poline
JB, Porteous DJ, Sisodiya SM, Starr JM, Sussmann J, Toga AW, Veltman DJ, Walter H,
Weiner MW; Alzheimer's Disease Neuroimaging Initiative (includes van Dyck CH);
EPIGEN Consortium; IMAGEN Consortium; Saguenay Youth Study Group, Bis JC,
Ikram MA, Smith AV, Gudnason V, Tzourio C, Vernooij MW, Launer LJ, DeCarli C,
Seshadri S; Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium, Andreassen OA, Apostolova LG, Bastin ME, Blangero J, Brunner HG,
Buckner RL, Cichon S, Coppola G, de Zubicaray GI, Deary IJ, Donohoe G, de Geus EJ,
Espeseth T, Fernández G, Glahn DC, Grabe HJ, Hardy J, Hulshoff Pol HE, Jenkinson M,
Kahn RS, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meyer-Lindenberg
A, Morris DW, Müller-Myhsok B, Nichols TE, Ophoff RA, Paus T, Pausova Z, Penninx
BW, Potkin SG, Sämann PG, Saykin AJ, Schumann G, Smoller JW, Wardlaw JM, Weale
ME, Martin NG, Franke B, Wright MJ, Thompson PM; Enhancing Neuro Imaging
Genetics through Meta-Analysis Consortium. Identification of common variants
associated with human hippocampal and intracranial volumes. Nat Genet. 2012 Apr
15;44(5):552-61. doi: 10.1038/ng.2250.
126. Chapman SB, Cotman CW, Fillit HM, Gallagher M, van Dyck CH. Clinical trials:
new opportunities. J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):773-80. Epub 2012
May 8.
127. Farlow M, Arnold SE, van Dyck CH, Aisen PS, MD, Snider BJ, Porsteinsson AP,
Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM,
Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer’s
disease. Alzheimers Dement. 2012 Jul;8(4):261-71. Epub 2012 Jun 5.
128. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen
H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E,
Andreasson U, Blennow K, Soares H, Albright C, Feldman HF, Berman RM. Safety and
tolerability of the gamma secretase inhibitor avagacestat in a Phase 2 study in mild-tomoderate Alzheimer’s disease. Arch Neurol, in press.
Papers Submitted
129. Galasko D, Bell J, Kupiec J, Sabbagh M, van Dyck CH, Thomas RG, Aisen PS.
38
C. H. van Dyck, M.D.
May 3, 2017
A randomized clinical trial of an inhibitor of RAGE-Aβ interactions in mild to moderate
AD, in preparation.
Chapters, Books, Letters
1. van Dyck CH, Seibyl JP, Zubal IG, Innis RB: Quantitation of neuroreceptors: a need to
increase imaging resolution? (Letter to the Editor) J Nucl Med 1996;37(11):1911-1912.
2. Arnsten AFT, van Dyck CH: Monoamine and acetylcholine influences on higher
cognitive functions in nonhuman primates: relevance to the treatment of Alzheimer's
disease, in Brioni JD, Decker MW (eds): Pharmacological Treatment of Alzheimer's
Disease: Molecular and Neurobiological Foundations. Wiley-Liss, Inc., New York, 1997,
pp. 63-86.
3. Naftolin FN, van Dyck CH. Commentary on: Shumaker SA, Legault C, Rapp SR, et al
for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and
mild cognitive impairment in postmenopausal women: the Womens Health Initiative
Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662. Published in:
First to Know (serial online http://www.menopause.org/news.html#june1); June 2003.
Cleveland, OH: The North American Menopause Society.
4. Kugaya A, Epperson CN, van Dyck, CH, Fujita M, Innis RB. Estradiol effects on the
postmenopausal brain (Letter to the Editor). Am J Psychiatry 2004;161(11):2136.
5. Mitsis EM, van Dyck CH. Neuroimaging in Alzheimer’s disease and Mild Cognitive
Impairment, in Sun M-K (ed): Research Progress in Alzheimer’s Disease and Dementia
(vol. 1). Nova Science, New York, 2006, pp. 1-24.
6. Tampi RR, van Dyck CH. Behavioral and Psychological Symptoms of Alzheimer’s
Disease, in Sun M-K (ed): Research Progress in Alzheimer’s Disease and Dementia (vol.
2). Nova Science, New York, 2007, pp. 251-272.
Published Abstracts
1. Inouye SK, van Dyck CH, Siegal AP, Horwitz RI: Clarifying confusion: A new
screening method for identifying acute confusional state. Clinical Research
1989;37(2):314A.
2. Alessi C, Balkin S, Pompei P, Inouye S, van Dyck C: Validity of the Confusion
Assessment Method: A new screening test for delirium in older patients. J Am Geriatr
Soc 1990;38(8):A42.
3. van Dyck CH, Woods SW, O'Malley SS, Price LH, McDougle CJ, Kosten TR: SPECT
regional cerebral blood flow in HIV disease. American Psychiatric Association 144th
Annual Meeting, New Research Program and Abstracts 1991, p.79.
39
C. H. van Dyck, M.D.
May 3, 2017
4. Thomas HM, van Dyck CH, Rosen MI, Waugh ME, Pearsall HR, Woods SW, Kosten
TR: Characterization of buprenorphine withdrawal. American Psychiatric Association
144th Annual Meeting, New Research Program and Abstracts 1991, p.84.
5. Rosen MI, Thomas HM, Pearsall HR, van Dyck CH, Woods SW, Kosten TR: Peptide
T for cognitively impaired HIV positive patients. American Psychiatric Association 144th
Annual Meeting, New Research Program and Abstracts 1991, p.173.
6. van Dyck CH, Woods SW, O'Malley SS, Martini BL, McDougle CJ, Price LH, Krystal
JH, Hoffer PB, Kosten TR: SPECT regional cerebral blood flow in HIV infected drug
abusers. Problems of Drug Dependence 1991, Proceedings of the 53rd Annual Scientific
Meeting, Committee on Problems of Drug Dependence, Inc.
7. Rosen MI, Bridge TP, O'Malley SS, Martini BL, O'Connor PG, Brett-Smith H, Thomas
HM, Pearsall HR, van Dyck CH, Woods SW, Kosten TR: Peptide T treatment of
cognitive impairment in HIV+ intravenous drug users. Problems of Drug Dependence
1991, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of
Drug Dependence, Inc.
8. Thomas HM, van Dyck CH, Rosen MI, Waugh ME, O'Connor PG, Pearsall HR, Hoffer
PB, Woods SW, Kosten TR: Regional cerebral blood flow changes in naltrexone
precipitated withdrawal from buprenorphine. Problems of Drug Dependence 1991,
Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug
Dependence, Inc.
9. Wallace EA, van Dyck CH, Zubal G, Pfau SE, Wisniewski G, Rosen MI, Pearsall HR,
Hoffer PB, Kosten TR, Woods SW: Regional cerebral blood flow effects of acute cocaine
infusion. Problems of Drug Dependence 1993, Proceedings of the 53rd Annual Scientific
Meeting, Committee on Problems of Drug Dependence, Inc.
10. van Dyck CH, McMahon TJ, Rosen MI, O'Malley SS, O'Connor PG, Pearsall HR,
Woods SW, Kosten TR: Methylphenidate for cognitive impairment in HIV-infected drug
abusers: A pilot study. Problems of Drug Dependence 1993, Proceedings of the 53rd
Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc.
11. Laruelle M, van Dyck CH, Bradberry CW, Malison R, Al-Tikriti M, Zoghbi SS, ZeaPonce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Displacement of [123I]IBF
equilibrium binding by d-amphetamine to measure in vivo dopamine release. J Nucl Med
1993;34(5):48P.
12. Laruelle M, Al-Tikriti M, van Dyck CH, Zoghbi SS, Zea-Ponce Y, Baldwin RM,
Charney DS, Hoffer PB, Innis RB: D-Amphetamine displacement of [123I]IBF
equilibrium binding in primates: A new paradigm to investigate d-amphetamine induced
dopamine release. International Meeting of Schizophrenia Research 1993.
40
C. H. van Dyck, M.D.
May 3, 2017
13. van Dyck CH, Laruelle M, Abi-Dargham A, Zoghbi SS, Zea-Ponce Y, Baldwin RM,
Charney DS, Hoffer PB, Innis RB: Three compartment modeling of [123I]IBF binding to
dopamine D2 receptors in human. Soc Neurosci Abstr 1993;19:1064.
14. Laruelle M, Bradberry CW, Al-Tikriti M, Abi-Dargham A, van Dyck CH, Malison
RT, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: DAmphetamine induced displacement of [123I]IBF equilibrium binding: A SPECT
paradigm to evaluate dopamine release. Scientific Abstracts, 32nd Annual Meeting of the
American College of Neuropsychopharmacology 1993.
15. van Dyck CH, Seibyl JP, Malison RT, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin
RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in dopamine transporter
binding in human striatum with [123I]ß-CIT SPECT. J Nucl Med 1994;35(5):11P.
16. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblat W, Zoghbi SS, Zea-Ponce Y,
Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine induced dopamine
release reduces the binding potential of [123I]IBF for dopamine D2/D3 receptors in
humans. J Nucl Med 1994;35(5):84P.
17. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblat W, Zoghbi SS, Zea-Ponce Y,
Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine induced displacement
of [I-123] IBF equilibrium binding – A SPECT paradigm to evaluate dopamine release.
Schizophrenia Research 1994;11(2):170-171.
18. van Dyck CH, Seibyl JP, Malison RT, Wallace E, Laruelle M, Zoghbi SS, Zea-Ponce
Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Age-related decline in dopamine
transporter binding with [123I]ß-CIT SPECT. Soc Neurosci Abstr 1994;20:387.
19. Laruelle M, Al-Tikriti M, Abi-Dargham A, van Dyck CH, Zoghbi SS, Zea-Ponce Y,
Baldwin RM, Charney DS, Hoffer PB, Innis RB: D-Amphetamine-induced reduction of
dopamine D2 availability in primates: Comparison between [123I]IBF and [123I]IBZM. Soc
Neurosci Abstr 1994;20:644.
20. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS,
Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB: SPECT imaging of striatal
dopamine release after amphetamine challenge in humans: Relationship between
subjective effects and dopamine release. Scientific Abstracts, 33rd Annual Meeting of the
American College of Neuropsychopharmacology 1994.
21. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, Price
LH, Leckman JF, Innis RB: [123I]ß-CIT SPECT imaging in Tourette's disorder. American
Psychiatric Association 148th Annual Meeting, New Research Program and Abstracts
1995.
22. Laruelle M, van Dyck CH, Abi-Dargham A, D'Souza D, Gil R, Erdos J, Rosenblatt
W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Charney DS, Krystal J, Innis RB:
41
C. H. van Dyck, M.D.
May 3, 2017
SPECT Imaging of dopamine release following amphetamine challenge in healthy
subjects and in patients with schizophrenia. J Nucl Med 1995;36(5):10P.
23. Malison RT, Best S, Wallace EA, van Dyck CH, Zoghbi SS, Zea-Ponce Y, Baldwin
RM, Laruelle M, Seibyl J, McCance-Katz E, Price LH, Kosten TR, Innis RB: SPECT
imaging of dopamine transporters in cocaine dependent and healthy control subjects with
[123I]ß-CIT. J Nucl Med 1995;36(5):31P.
24. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M,
Hoffer PB: Comparison of 99mTc-HMPAO and 99mTc-ECD cerebral SPECT images in
Alzheimer's disease. J Nucl Med 1995;36(5):108P.
25. van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Wisniewski G, Narayan M,
Arnsten AFT, Hoffer PB: Effects of the acetylcholine releaser linopirdine on SPECT
rCBF and cognitive function in Alzheimer's disease. J Nucl Med 1995;36(5):238P.
26. Narayan M, Lin CH, Robinson R, Cellar J, Hoffer PB, van Dyck CH: Comparison of
99mTc-HMPAO and 99mTc-ECD cerebral SPECT images in Alzheimer's disease. Am J
Geriatr Psychiatry 1995;3:268-269.
27. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, et al: SPECT imaging of striatal
dopamine release after amphetamine challenge in humans – relationship between
subjective effects and dopamine release. Schizophrenia Research 1995;15(1-2):89-90.
28. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, Erdos J, D'Souza D, Rosenblatt
W, Krueger S, McCance-Katz E, Bremner D, Abi-Saab D, Zea-Ponce Y, Zoghbi SS,
Baldwin RM, Hoffer PB, Krystal J, Charney DS, Innis RB: SPECT Imaging of synaptic
dopamine activity in drug free schizophrenic patients. Soc Neurosci Abstr 1995;21:261.
29. van Dyck CH, Lin CH, Robinson R, Cellar J, Narayan M, Arnsten AFT, Hoffer PB:
Effects of the acetylcholine releaser linopirdine on SPECT rCBF and cognitive function
in Alzheimer's disease. Soc Neurosci Abstr 1995;21:1996.
30. Laruelle M, Abi-Dargham A, Gil R, van Dyck CH, Erdos J, D'Souza CD, Rosenblatt
W, McCance-Katz E, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J,
Charney DS, Innis RB: SPECT imaging of synaptic dopamine release in drug free
schizophrenic patients. Scientific Abstracts, 34th Annual Meeting of the American
College of Neuropsychopharmacology 1995.
31. Laruelle M, AbiDargham A, vanDyck CH, et al. Increased striatal dopamine release in
drug free schizophrenic subjects. Biol Psychiatry 1996;39(7):208.
32. Laruelle M, AbiDargham A, Gil R, et al. SPECT imaging of synaptic dopamine
release in drug free schizophrenic patients: An experimental validation of the dopamine
hypothesis of schizophrenia. Schizophrenia Research 1996;18 (2-3):XIID3.
42
C. H. van Dyck, M.D.
May 3, 2017
33. Laruelle M, van Dyck CH, Abi-Dargham A, Rosenblatt W, Zoghbi SS, Baldwin RM,
Hoffer PB, Charney DS, Innis RB: Age related decline in amphetamine-induced
dopamine release measured with SPECT and [123I]IBZM in healthy subjects. J Nucl Med
1996;37(5):33P.
34. van Dyck CH, Seibyl JP, Laruelle M, Best S, Sheff K, Marek KL, Malison RT,
Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB, Innis RB: Aging effects
with [123I]ß-CIT SPECT: analysis of gender, striatal subregion, and neuropsychological
correlates. J Nucl Med 1996;37(5):272P.
35. van Dyck CH, Lin CH, Robinson R, Cellar J, Arnsten AFT, Hoffer PB: Effects of the
acetylcholine-releaser linopirdine on SPECT regional cerebral blood flow and cognitive
function in Alzheimer's disease. Am J Geriatr Psychiatry 1996;4(4):339-340.
36. van Dyck CH, Seibyl JP, Laruelle M, Sheff K, Marek KL, Zoghbi SS, Zea-Ponce Y,
Baldwin RM, Charney DS, Innis RB: Age-related decline in dopamine transporters with
[123I]ß-CIT SPECT: analysis of gender, striatal subregion, and neuropsychological
correlates. Soc Neurosci Abstr 1996;22:1201.
37. van Dyck CH, Seibyl JP, Laruelle M, Sheff K, Marek KL, Zoghbi SS, Zea-Ponce Y,
Baldwin RM, Charney DS, Innis RB: Age-related decline in dopamine transporters with
[123I]ß-CIT SPECT: Analysis of gender, striatal subregion, and neuropsychological
correlates. Scientific Abstracts, 35th Annual Meeting of the American College of
Neuropsychopharmacology 1996, p.281.
38. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Seibyl JP, Baldwin
RM, Krystal JH, Charney DS, Innis RB: SPECT imaging of amphetamine-induced
dopamine release in drug free schizophrenic subjects. Scientific Abstracts, 35th Annual
Meeting of the American College of Neuropsychopharmacology 1996, p.26.
39. van Dyck CH, Seibyl JP, Fowler JS, Wong DF, Jeste DV: Imaging the aging
dopamine system. Am J Geriatr Psychiatry 1997, abstract submitted.
40. van Dyck CH, Tan P-Z, Baldwin RM, Ramsby Q, Rich DA, Garg PK, Ng CK, Soufer
R, Charney DS, Innis RB: PET quantification of 5-HT2A/C receptors in the human brain: a
constant infusion paradigm with [F-18]altanserin. J Nucl Med 1997;38(5):70P.
41. van Dyck CH, Gelernter JE, MacAvoy MG, Avery RA, Criden M, Okereke O, Seibyl
JP, Hoffer PB: Increased parietal rCBF asymmetry in Alzheimer's disease lacking the
apolipoprotein E 4 allele. J Nucl Med 1997;38(5):95P-96P.
42. Tan P-Z, Baldwin RM, van Dyck CH, Amici L, Al-Tikriti M, Roth B, Khan N,
Fowler JS, Shea C, Soufer R, Charney DS, Innis RB: Identity and receptor binding of
radiometabolites of the 5-HT2A/2C ligand [F-18]altanserin. J Nucl Med
1997;38(5):287P.
43
C. H. van Dyck, M.D.
May 3, 2017
43. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden MC, Okereke O, Seibyl
JP, Hoffer PB: The absence of an apolipoprotein E 4 allele is associated with increased
parietal rCBF asymmetry in Alzheimer's disease. Am J Geriatr Psychiatry 1997 abstract
submitted.
44. Baldwin RM, Tan P-Z, van Dyck CH, Al-Tikriti M, Amici L, Roth B, Khan N, Soufer
R, Charney DS, Innis RB: Radiometabolites of [18F]altanserin in rats and humans: 4-(p[18F]fluorobenzoyl)piperidine and [18F]altanserinol. J Labeled Compd Radiopharm
1997;40:SI 133-135.
45. Tan P-Z, Baldwin RM, Soufer R, van Dyck CH, Charney DS, Innis RB: Application
of the deuterium isotope effect to enhance PET signal by impeding tracer metabolism:
synthesis of deuterium and fluorine-18 dual-labeled altanserin and its nitro precursor. J
Labeled Compd Radiopharm, 1997;40:SI 130-132.
46. Marek K, Innis R, Fussell B, et al. 1231 beta-CIT and SPECT: An imaging biomarker
of Parkinson's disease progression. Neurology 1998;50(4):S40002.
47. van Dyck CH, Tan P-Z, Staley J, Baldwin RM, Al-Tikriti M, Garg PK, Ng CK,
Soufer R, Charney DS, Innis RB: PET quantification of 5-HT2A receptors: a constant
infusion paradigm with [F-18]altanserin. J Nucl Med 1998;39(5):136P.
48. Tan P-Z, Soares J, Baldwin RM, van Dyck CH, Soufer R, Seibyl JP, Charney DS,
Innis RB: H-2 and F-18 dual-labeled altanserin as a metabolically resistant PET ligand for
serotonin-2A (5-HT2A) receptor. J Nucl Med 1998;39(5):21P.
49. Verhoeff NPLG, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Baldwin
RM, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, van Dyck CH, Krystal JH, Innis RB:
Nicotine use effects on brain benzodiazepine receptors in schizophrenia measured by
[123I]iomazenil SPECT. Problems of Drug Dependence 1999, Proceedings of the 61st
Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc.
50. van Dyck CH, Soares J, Tan P-Z, Staley J, Baldwin RM, Amici LA, Garg PK, Ng
CK, Charney DS, Innis RB: Improved PET quantification of 5-HT2A receptors with [F18]deuteroaltanserin: a constant infusion paradigm. J Nucl Med 1999;40(5):273P.
51. Basso M, Yang J, Gelernter J, Half LM, MacAvoy MG, van Dyck CH:
Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s
disease. Soc Neurosci Abstr 1999;25:1058.
52. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Joel Gelernter J:
Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s
disease. Scientific Abstracts, 38th Annual Meeting of the American College of
Neuropsychopharmacology 1999.
53. Tan P-Z, Soares JC, Staley JK, Seibyl JP, Baldwin RM, van Dyck CH, Al-Tikriti MS,
Fu X, Charney DS, Innis RB: Utilization of deuterium isotope effect to enhance specific
44
C. H. van Dyck, M.D.
May 3, 2017
brain uptake of [18F]altanserin, a 5-HT2A radiotracer for PET. J Labeled Compd
Radiopharm 1999;42 Suppl. 1:66-67.
54. van Dyck CH: SPECT rCBF and MRI volumetric correlates of apolipoprotein E 4 in
Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8:57-58.
55. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Gelernter J:
Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s
disease. Proceedings of the 1st International Meeting, Alzheimer’s Imaging Consortium,
July 8, 2000, Washington, D.C.
56. van Dyck CH, Basso M, Yang J, Half LM, MacAvoy MG, Varma P, Gelernter J:
Apolipoprotein E 4 allele is associated with atrophy of the amygdala in Alzheimer’s
disease. Neurobiol. Aging 2001;22(2):24.
57. van Dyck CH: Neuroimaging in Alzheimer’s disease: relevance for the development
of therapeutic agents. CNS Drug Rev 2000;6(Supplement 1):26-27.
58. Lappalainen J, Kranzler H, Malison R, Price L, van Dyck CH, Rosenheck RA,
Kramer J, Southwick S, Charney DS, Krystal JK, Gelernter J: Neuropeptide Y LEU7PRO
polymorphism is associated with alcohol dependence in a large population sample from
the U.S. Scientific Abstracts, 39th Annual Meeting of the American College of
Neuropsychopharmacology 2000.
59. Kugaya A, Epperson N, van Dyck CH, Zoghbi, S, Hou Y, Fujita M, Staley J, Garg P,
Seibyl J, Innis R: The effect of estrogen on brain serotonin2A receptors measured by PET
in postmenopausal women. Soc Neurosci Abstr 2001.
60. van Dyck CH, Seibyl JP, Malison RT, Zoghbi SS, Baldwin RM, Innis RB: Agerelated decline in dopamine transporters: analysis of striatal subregions, nonlinear effects,
and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10(2):62.
61. Staley JK, Mason G, Petrakis I, Zoghbi SS, Verhoeff NPLG, Seibyl JP, van Dyck CH,
Innis RB, Baldwin R, Krystal JH. Assessment of cortical GABA function in acutely (< 7
days) detoxified alcohol dependent patients. J Nucl Med 2002;43(5):109P.
62. Fujita M, van Dyck CH, Ichise M, Zoghbi, SS, Tamagnan G, Bozkurt A, Seneca N,
Mukhin AG, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP,
Baldwin RM, Innis RB: Quantification of brain nicotinic acetylcholine receptors in
humans using 123I-5-I-A-85380. J Nucl Med 2002;43(5):110P.
63. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Laruelle M, Staley JK, Baldwin
RM, Innis RB, Gelernter J: 9-Repeat allele of the dopamine transporter gene is associated
with increased dopamine transporter protein availability. J Nucl Med 2002;43(5):107P.
64. Staley JK, Mason G, Gottschalk C, Petrakis I, Zoghbi S, Verhoeff NP, Seibyl JP, van
Dyck CH, Innis RB, Baldwin RM, Krystal JH: GABA system alterations in human
45
C. H. van Dyck, M.D.
May 3, 2017
alcohol dependence: Insights from multimodal neurochemical imaging. Neuroscience
Addiction International Conference, Mexico City, June 2002.
65. Fujita M, van Dyck CH, Ichise M, Zoghbi S, Tamagnan G, Bozkurt A, Seneca N,
Mukhin A, Vaupel B, Horti A, Koren A, Khan S, Early M, Kimes A, London E, Seibyl J,
Baldwin R, Innis R: Whole-body biodistribution, radiation-absorbed dose, and brain
SPECT imaging with [I-123]5-I-A-85380 in healthy human subjects. Neuroimage
2002;11:S8.
66. Volkow ND, Swanson JM, Waldman E, Gainetdinov R, Spencer T, van Dyck CH:
Dopamine transporters in ADHD: Increased, decreased, or unchanged? (Study Group)
Scientific Abstracts, 41st Annual Meeting of the American College of
Neuropsychopharmacology 2002.
67. Tariot P, Farlow M, Grossberg G, van Dyck CH, Gergel I, Graham S, Jin J:
Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment
of moderate to severe Alzheimer’s disease. Alzheimer’s and Parkinson’s Diseases: New
Perspectives, 6th International Conference, Seville Spain, May 8-12, 2003.
68. van Dyck, CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, Baldwin
RM, Innis RB, Gelernter J: Central serotonin transporter availability measured with
[123I]ß-CIT SPECT in relation to serotonin transporter genotype. J Nucl Med
2003;44(5):68P-69P.
69. Staley JK, Petrakis I, Gottschalk C, Ruff E, Frohlich E, Weinzimmer D, Seibyl JP,
van Dyck CH, Baldwin RM, Krystal JH: [123I]Iomazenil SPECT imaging demonstrates no
change in cortical benzodiazepine-GABA-A receptors in long term sober alcoholics.
Annual Meeting for Research Society on Alcoholism, June-July 2003.
70. Staley JK, Petrakis I, Gottschalk C, Seibyl JP, Verhoeff P, Perry E, van Dyck CH,
Baldwin RM, Krystal JH: Benzodiazepine receptor availability in recently abstinent
alcohol dependent males: relationship to craving, withdrawal and smoking. Scientific
Abstracts, 42nd Annual Meeting of the American College of Neuropsychopharmacology
2003.
71. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of
memantine in Alzheimer's disease. Neurobiol Aging 2004;25 (Suppl. 2):S186.
72. Cummings JL, van Dyck C, Schmitt FA, et al. Functional and behavioral effects of
memantine in Alzheimer's disease. Int J Neuropsychopharmacol 2004;7(Suppl. 1): S208.
73. Karlawish JH, James BD, Kim S, Knopman D, van Dyck CH, Marson D. Alzheimer's
disease patient and caregiver attitudes about proxy informed consent. Neurobiol Aging
2004;25 (Suppl. 2):S345.
74. Cummings J, van Dyck C, Schmitt F, et al. Functional and behavioral effects of
memantine in Alzheimer's disease. J Am Geriatr Soc 2004;52(4):S14.
46
C. H. van Dyck, M.D.
May 3, 2017
75. van Dyck C, Ferris S, Graham S, et al. Response to memantine treatment in moderate
to severe Alzheimer's disease. J Am Geriatr Soc 2004;52(4):S155.
76. Tariot PN, van Dyck CH, Schmitt FA, Graham SM, Olin JT, Jin J, Cummings JL.
Functional and behavioral effects of memantine in Alzheimer’s disease. American
Psychiatric Association Annual Meeting, New York, May 1-6, 2004.
77. Staley JK, van Dyck CH, Tamagnan G, Baldwin RM, Weinzimmer D, Riccardi P,
Krystal JH, Seibyl JP. Test-retest reliability of [I-123]5-IA-85830 for SPECT imaging of
ß2-nicotinic acetylcholine receptors. J Nucl Med 2004;45(5).
78. Staley JK, Krishnan-Sarin S, O'Malley S, Cosgrove KP, Baldwin RM, Tamagnan GD,
Seibyl JP, Jatlow P, van Dyck CH. [I-123]5-IA-85830 SPECT imaging of ß2-nicotinic
acetylcholine receptors in recently abstinent human tobacco smokers. Neuroimage
2004;22(Suppl. 2):T161.
79. Staley JK, van Dyck CH, Tamagnan G, Baldwin RM, Weinzimmer D, Riccardi P,
Krystal JH, Seibyl JP. Reproducibility of equilibrium modeling of [I-123]5-IA-85830
SPECT measurements of ß2-nicotinic acetylcholine receptors. Neuroimage
2004;22(Suppl. 2):T195.
80. Staley JK, Krishnan-Sarin S, Kranztler E, Frohlich E, O’Malley S, Cosgrove K,
Baldwin RM, Tamagnan G, Seibyl JP, Jatlow P, London ED, van Dyck CH. [I-123] 5-IA85380 SPECT imaging of ß2 nicotinic acetylcholine receptors in tobacco smokers. Soc
Neurosci Abstr 2004.
81. van Dyck CH, Cummings J, Schmitt F, Graham SM, Olin JT, Jin J, Tariot PN.
Functional and behavioral effects of memantine in Alzheimer's disease. European
Neuropsychopharmacology 2004;14: S334-S335.
82. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Graham SM, Bell
JM. Efficacy of memantine for cognitive deficits of mild to severe Alzheimer’s disease.
Neuropsychopharmacology 2004:29(S1):S131.
83. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Resnick EM.
Efficacy of memantine for cognitive deficits of mild to severe Alzheimer’s disease.
American Association for Geriatric Psychiatry, San Diego CA, March 3-6, 2005.
84. Petersen, RC, Thal, LJ, Grundman M, Thomas RG, Bennett D, Doody R, Ferris S,
Galasko D, Kaye J, Levey A, Pfeiffer E, van Dyck, CH: Donepezil And Vitamin E In
Mild Cognitive Impairment. J Am Geriatr Soc 2005;53(4):S14.
85. Mitsis E, van Dyck CH, McKee S, Terlecki M, Haile CN, Brenner E, Tamagnan GT,
Seibyl JP, Staley JK. Displacement of cortical and subcortical [123-I]5-IA-85380 uptake
by cigarette smoke in human brain. J Nucl Med 2005;46(5).
47
C. H. van Dyck, M.D.
May 3, 2017
86. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D,
Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Donepezil and
vitamin E in the progression of Mild Cognitive Impairment to Alzheimer’s disease: a
hazard-ratio analysis. International Conference on AD Prevention, June 18, 2005,
Washington, D.C.
87. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D,
Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Operational criteria
for patient recruitment in trials of Mild Cognitive Impairment. International Conference
on AD Prevention, June 18, 2005, Washington, D.C.
88. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH,
Bagwell V, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ. Sex,
apolipoprotein E 4 status, and hippocampal volume in mild cognitive impairment.
International Conference on AD Prevention, June 18, 2005, Washington, D.C.
89. Schmitt FA, van Dyck CH, Feldman, H, Tariot PN, Peskind ER, Resnick EM.
Efficacy of Memantine on cognition in mild to severe Alzheimer’s disease. American
Psychiatric Association Institute on Psychiatric Services, October 5-9, 2005, San Diego,
CA.
90. Mitsis EM, van Dyck CH, Krantzler E, McKee S, Perry E, Terlecki M, Brenner E,
Jatlow P, Baldwin R, Tamagnan GD, Seibyl JP, Staley JK. (2005). Prolonged occupancy
of nicotinic acetylcholine receptors by nicotine in human brain: A preliminary study.
Annual Meeting of the Society for Research on Nicotine and Tobacco.
91. Staley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van
Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT
imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy
and schizophrenic smokers. Neuroimage 2006;31(Suppl. 2):T154-T154.
92. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy
MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test
performance in cognitively normal first-degree relatives at varying genetic risk for
Alzheimer’s disease. Human Amyloid Imaging 2010 Meeting Abstracts. Toronto 2010
April 9.
93. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy
MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test
performance in cognitively normal first-degree relatives at varying genetic risk for
Alzheimer’s disease. Human Amyloid Imaging 2011 Meeting Abstracts. Miami Beach
2011 Jan 14.
94. van Dyck CH, Brück A, Barcelos NM, Benincasa AL, Planeta-Wilson B, MacAvoy
MG, Ding YS, Gelernter J, Carson RE. Amyloid-ß burden and neuropsychological test
performance in cognitively normal first-degree relatives at varying genetic risk for
Alzheimer’s disease. ICAD 2011. Paris 2011 Jul 16-21.
48
C. H. van Dyck, M.D.
May 3, 2017
95. Salloway S, Porsteinsson AP, Sperling R, Keren R, van Dyck CH, Tariot PN, Gilman
S, Crans G, Hernandez C, Quinn G, Bairu M, Cedarbaum JM, Pastrak A, Abushakra S
for the ELND005-AD201 Investigators. Safety and Efficacy Results of a Phase 2
Randomized, Placebo-Controlled, Dose-Ranging Study of ELND005 (Scyllo-inositol) in
Mild to Moderate Alzheimer’s Disease. ICAD 2011. Paris 2011 Jul 16-21.
96. Porsteinsson AP, Sperling R, Salloway S, Keren R, van Dyck CH, Tariot PN, Arnold
DL, Crans G, Hernandez C, Liang E, Bairu M, Cedarbaum JM, Pastrak A, Abushakra S
for the ELND005-AD201 Investigators. Imaging and Cerebrospinal Fluid Biomarker
Results of a Phase 2 Dose-Ranging Study of ELND005 (Scyllo-inositol) in Mild to
Moderate Alzheimer’s Disease. ICAD 2011. Paris 2011 Jul 16-21.
97. Salloway S, Berman RM, Coric V, Brody M, Andreasen N, van Dyck CH, Soininen
H, Thein S, Shiovitz T, Kumar S, Pilcher G, Colby S, Rollin L, Feldman HH. Safety and
Tolerability of BMS-708163 in a Phase 2 Study in Mild-to-Moderate Alzheimer’s
Disease (AD). ICAD 2011. Paris 2011 Jul 16-21.
49